# Gait metrics analysis utilizing single-point inertial measurement units: a systematic review

Ralph Jasper Mobbs<sup>1,2,3</sup>, Jordan Perring<sup>1,2</sup>, Suresh Mahendra Raj<sup>1</sup>, Monish Maharaj<sup>1,2</sup>, Nicole Kah Mun Yoong<sup>1,2</sup>, Luke Wicent Sy<sup>4</sup>, Rannulu Dineth Fonseka<sup>1,2</sup>^, Pragadesh Natarajan<sup>1,2</sup>, Wen Jie Choy<sup>1,2</sup>

<sup>1</sup>Faculty of Medicine, University of New South Wales, Sydney, Australia; <sup>2</sup>NeuroSpine Surgery Research Group (NSURG), Sydney, Australia; <sup>3</sup>Department of Neurosurgery, Prince of Wales Hospital, Sydney, Australia; <sup>4</sup>Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia

*Contributions:* (I) Conception and design: All authors; (II) Administrative support: RJ Mobbs, J Perring; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Ralph Jasper Mobbs. Faculty of Medicine, University of New South Wales, Sydney, Australia. Email: r.mobbs@unsw.edu.au.

**Background:** Wearable sensors, particularly accelerometers alone or combined with gyroscopes and magnetometers in an inertial measurement unit (IMU), are a logical alternative for gait analysis. While issues with intrusive and complex sensor placement limit practicality of multi-point IMU systems, single-point IMUs could potentially maximize patient compliance and allow inconspicuous monitoring in daily-living. Therefore, this review aimed to examine the validity of single-point IMUs for gait metrics analysis and identify studies employing them for clinical applications.

**Methods:** The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA) were followed utilizing the following databases: PubMed; MEDLINE; EMBASE and Cochrane. Four databases were systematically searched to obtain relevant journal articles focusing on the measurement of gait metrics using single-point IMU sensors.

**Results:** A total of 90 articles were selected for inclusion. Critical analysis of studies was conducted, and data collected included: sensor type(s); sensor placement; study aim(s); study conclusion(s); gait metrics and methods; and clinical application. Validation research primarily focuses on lower trunk sensors in healthy cohorts. Clinical applications focus on diagnosis and severity assessment, rehabilitation and intervention efficacy and delineating pathological subjects from healthy controls.

**Discussion:** This review has demonstrated the validity of single-point IMUs for gait metrics analysis and their ability to assist in clinical scenarios. Further validation for continuous monitoring in daily living scenarios and performance in pathological cohorts is required before commercial and clinical uptake can be expected.

Keywords: Accelerometry; gait analysis; wearable electronic devices

Received: 12 April 2021; Accepted: 27 August 2021; Published: 20 January 2022. doi: 10.21037/mhealth-21-17 View this article at: https://dx.doi.org/10.21037/mhealth-21-17

### Introduction

Human gait is affected by ageing as well as numerous musculoskeletal and neurological ailments. Consequently,

gait analysis has wide-ranging clinical applications from diagnosis and severity assessment as well as evaluation of intervention and rehabilitation efficacy in neurological and

^ ORCID: 0000-0002-7748-5101.

#### Page 2 of 27

orthopedic conditions (1-8) to identifying falls risk and frailty status (9,10). Qualitative and subjective measures generally constitute routine clinical gait analysis, with patient self-reporting and clinician observation sometimes integrated with clinical tests such as the Timed-Up-And-Go and 6-minute walking test (6MWT) (11). These approaches impose significant interobserver inaccuracies and deny appreciation of kinematic and kinetic intricacies that can be obtained from quantitative gait assessment (12).

The gold-standard for quantitative gait analysis, optoelectronic stereophotogrammetry, features infrared cameras that capture three-dimensional trajectories of reflective markers placed on the subject that are processed to accurately assess spatio-temporal and kinematic variables of gait (13). Stereophotogrammetry is often combined with force plates that measure ground-reaction forces (GRF) to determine kinetic forces and electromyography (EMG) systems to measure muscle activity during gait. However, these systems are expensive, time-consuming, and require expert operation and equipment. Furthermore, restriction of their performance to dedicated laboratory settings limits portability, access and external validity of measures obtained to free-living gait (11).

In response, wearable sensors (goniometers, EMG systems, sensing fabric etc.), particularly accelerometers alone or combined with gyroscopes and magnetometers in an inertial measurement unit (IMU), are proving to be the logical alternative for gait analysis. Cheap, small and portable, wearables could potentially enable continuous gait metrics analysis in daily living (14-17). Furthermore, fast preparation and processing negate the need for expert operation, enhancing practicality. Multi-point IMU systems have been validated against standards (18-23) and employed clinically for gait metrics analysis (24-28); however, issues with intrusiveness and consistency of complex sensor placement limit real-life adoption (29). Although not as accurate and reliable as multi-point IMU systems (30), single-point IMUs have nonetheless demonstrated enormous potential. They have clinical uses, such as with the assessment of Parkinson's Disease (PD) severity (31,32) and the evaluation of falls risk in preventative health care (33,34), and personal uses, such as with the tallying of daily steps in consumer-grade watches (4,35). Commonly used single-point IMUs and their specifications are detailed for comparison in *Table 1*.

Moreover, presuming validated accuracy is demonstrated, single-point IMUs could potentially maximize patient compliance and comfort and allow inconspicuous monitoring in daily-living. Consequently, any future mass uptake of IMUs in clinical and commercial settings is likely to be dependent upon the validation and applications of single-point IMUs and not of multi-point IMU systems. Therefore, this review will provide a synopsis of inertial sensor principles, practical considerations and gait metrics analysis capabilities before examining the validity and clinical applications of single-point devices for gait analysis. We present the article in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA) checklist (available at https://dx.doi.org/10.21037/mhealth-21-17).

### Inertial sensors: principles and practical considerations

Inertial sensors, accelerometers and gyroscopes, are often fabricated into microelectromechanical systems (MEMS) alone or together as an IMU and employed for gait metrics analysis (78).

Accelerometers measure acceleration along their sensitive axis, ranging from uni-axial to the commonly employed tri-axial sensitivity which allows appreciation of movement along the antero-posterior, horizontal and vertical planes. However, current devices are susceptible to drift errors due to change in mechanical or electrical properties and noise from amplified mechanical motions. Furthermore, the measured acceleration comprises both the inertial acceleration associated with changes in velocity, and gravitational acceleration superimposed along the accelerometer's sensitive axes. Removing this confounding effect of gravity can be difficult (78). To appreciate velocity and distance, numerical integration of acceleration data is required, causing noise and drift errors to accumulate, imposing significant limitations on long-term accelerometer employment. Without compensation for this drift, readings become useless. Compensation requires frequent accelerometer recalibration, achieved through zero-velocity updates (ZUPT), using an external event indicating an instantaneous null in movement such as a footstep (79).

Gyroscopes measure angular velocity, demonstrating greater accuracy than accelerometers as measurement is absolute with no external information considered (80). However, gyroscopes only return rate of change of angular position; to detect relative orientation, integration of the signal is required. This leads to accumulation of drift errors and noise, similar to accelerometers (80). Furthermore, lack of an initial reference compared to accelerometers means gyroscopes cannot be recalibrated, resulting in accumulation of errors and limited long-term

ble 1 Cor	nmon single-point IMUs and thei Sensor	r specifications Placement	Gait metrics demonstrated to be captured	Component MEMS sensors	Other known specifications
36-40)	Locometrix	Lower back, L3-4	GV and stride frequency, length, symmetry and regularity	Tri-axial accelerometer	100 Hz frequency of data capture, resolution 0.001 g
45)	MT product line IMUs (Xsens, Enschede, The Netherlands)	Lower back, L4	MTx was able to capture GV, cadence, step regularity, stride regularity, gait symmetry, step time, step time variability, RMS and HR	Tri-axial accelerometer, gyroscope, and magnetometer	According to MTi (newer than MTx) specifications: Output frequency up to 2 kHz. Accelerometer range 16 g. Gyroscope range 2,000 deg/s. 12.1×12.1×2.55 mm³ (without encasing). 0.6 grams (without encasing)
47)	Pi-node (Philips, The Netherlands)	Lower back, L4	GV, step time, step time variability, cadence, stride length, stride length variability and non-linear measures (gait variability and symmetry)	Tri-axial accelerometer	100 Hz frequency of data capture
59)	DynaPort IMUs (McRoberts, The Hague, The Netherlands)	Lower back	Step count, GV, stride time variability, stride regularity and cadence	Tri-axial accelerometer, and gyroscope	100 Hz frequency of data capture. 106.6x58x11.5 mm <sup>3</sup> .55 grams. 14-day maximum measurement duration
64)	G-walk (BTS Bioengineering Milan, Italy)	Lower back, L5	GV, SL, stride length and cadence. Gait cycle duration, stance duration, swing duration and double support duration	Tri-axial accelerometer, gyroscope, and magnetometer	Accelerometer range 2, 4, 8, or 16 g (configurable). Gyroscope range 250, 500, 1,000, or 2,000 deg/s (configurable). Magnetometer range ±1,200 uT. Accelerometer sampling rate 4–1,000 Hz (configurable). Gyroscope sampling rate 4 to 8,000 Hz (configurable). 37 grams
66)	Physilog product line (Gaitup, Lausanne, Switzerland)	Chest, 5 cm below sternal notch	GV, non-linear measures (gait stability), RMS and walk-ratio	Tri-axial accelerometer and gyroscope	According to Physilog5 specifications: Accelerometer range 16 g. Gyroscope up to 2,000 deg/s. 26.5×10×47.5 mm <sup>3</sup>
68)	GENEActiv (Activinsights, Kimbolton, England)	Lower back or wrist	Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability)	Tri-axial accelerometer	100 Hz sampling frequency
69-71)	Axivity AX3 (Axivity, York, England)	Lower back, L5	Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, stance time asymmetry, SL asymmetry, step velocity, SL, swing time variability, step time variability, stance time variability, GV and SL variability	Tri-axial accelerometer	Up to 8 g. 100 Hz. Waterproof. 23×32.5×7.6 mm³, 11 g weight. Accelerometer range 2, 4, 8, or 16 g (configurable). Accelerometer sampling rate 12.5–3,200 Hz (configurable)

Table 1 (continued)

Lable I (con	tinned)				
References	Sensor	Placement	Gait metrics demonstrated to be captured	Component MEMS sensors	Other known specifications
(72)	MIMAMORI-Gait system (LSI Medience Corp, Tokyo, Japan)	Back of waist	GV, SL, cadence, step time, step time variability and double support time	Tri-axial accelerometer	100 Hz frequency of data capture 75×50×20 mm³, 120 grams
(73)	activPAL (PAL Technologies, Glasgow, Scotland)	Upper thigh	Step count, cadence	Uni-axial accelerometer	20 Hz frequency of data capture. 53.0×35.0×7.0 mm³. 20 grams
(74,75)	Actigraph wGT3X-BT activity monitor (Actigraph, Pensacola, FL, USA)	Lateral waist	Cadence, stride regularity and non- linear measures (intensity, dynamic stability)	Tri-axial accelerometer	50 Hz frequency of data capture. Acceleration range 8 g
(76,77)	e-AR sensor	Behind ear	Stride duration and step time asymmetry. Gait asymmetry	Tri-axial accelerometer	
(4)	Apple Watch (Apple, San Francisco, CA, USA)	Wrist	Daily step count, gait velocity, estimated caloric expenditure, distance travelled	Tri-axial accelerometer and gyroscope	
IMU, inertia root-mean s	al measurement unit; g, magnitur square; HR, harmonic ratio.	de of acceleratic	on due to gravity, 9.8 m/s <sup>2</sup> ; MEMS, micr	oelectromechanical system	is; GV, gait velocity; SL, step length; RMS,

precision (80). This limitation is often minimized by incorporating a magnetometer in the IMU, able to calibrate sensor orientation with reference to the Earth's magnetic field. However, these devices are prone to interference by magnetic fields created by other devices (80).

### Inertial sensor-based gait analysis

While single-point inertial sensors are unable to appreciate kinetic and many kinematic variables of gait, they can determine spatio-temporal parameters. Spatiotemporal parameters are of importance clinically, as they objectively characterize key gait events (GE) and common gait abnormalities (81). A plethora of spatio-temporal parameters are employed in the literature, with some [such as gait velocity (GV) and gait regularity in predicting the staging of PD severity] being more relevant than others in different clinical scenarios (31,32). This review focusses on spatio-temporal parameters based on a validated model (82,83) and clinical guidelines from The Biomathics and Canadian Gait Consortiums Initiative (84). These parameters encompass the mean, variability and asymmetry of temporal (cadence, step time, stride time, stance duration, swing duration, single-support duration, double-support duration) and spatial [step length (SL), stride length, GV step width] components of gait.

As acceleration data retains a time-series nature when extracted, by determining GEs such as heel-strike (HS) and toe-off (TO) within the gait cycle, mean temporal parameters can be quantified. Methods for GE detection are based on signal feature extraction of peaks, valleys or zerocrossings from raw accelerometric or gyroscopic data that may indicate a HS or TO (78). This can be complemented by applying hidden Markov models or Gaussian continuous wavelet-transformation (CWT) to increase GE detection accuracy (29). These methods have been implemented for single sensors placed on the trunk (85-87), waist (88,89), shank (90), ear (76) and foot (91,92). A thigh-based singlepoint IMU, the Activpal (PAL Technologies, Glasgow, Scotland), has also been used to measure mobility (73,93). However, this sensor has, to our knowledge, not analysed gait metrics beyond step identification in a single-point system.

Spatial parameter estimation proves more difficult due to the aforementioned technical limitations of inertial sensors (29). Current methods are based on abstraction models (e.g., machine-learning, linear regressive models), locomotion models [e.g., inverted pendulum (IP), double-

IP] and numerical integration. Those employed for singlepoint sensors include: direction integration (88), linear regression models (89), IP model with double-integration of antero-posterior (86,87) or vertical acceleration from trunk sensors (85); IP model with double integration of AP-acceleration from a foot sensor (91); double-IP model with integration of angular velocity of the shank (90); and autocorrelation procedures also able to determine temporal parameters, and a measure of regularity and symmetry (94). However, the requirement of numerical integration in these models causes accumulation of drift errors (78). Drift compensation is performed using kinematical reset through ZUPT by assuming foot velocity as zero (91) and shank inclination as vertical during midstance (90); however, these methods only prevent growth of drift error without minimizing the already accumulated error (29). As zero-velocity reset is not possible with trunk sensors due to continuous pelvic motion, drift correction is achieved by applying a highpass (86) or Kalman filter (88) to retrospectively correct errors, occasionally in combination with direct and inverse integration at every step (88). However, correction efficacy may be limited in pathological gait where vertical trunk acceleration amplitude is lower and variability higher (78).

Linear measures of spatio-temporal variability and asymmetry are subsequently determined from mean spatio-temporal values, commonly expressed as the standard deviation or coefficient of variation and the absolute difference between left and right mean values respectively (95).

In addition to these traditional spatio-temporal parameters, accelerometer-based systems and non-linear calculations introduce new measures (11). Although these complex non-linear, autocorrelation and acceleration-based measures are dimensionless and unable to be validated against a standard, they are employed extensively clinically. Non-linear measures derived from the theory of stochastic dynamics (e.g., phase plot analysis, fractal-scaling index, sample entropy, Lyapunov exponents) allow appreciation of dynamic fluctuations and patterns between gait cycles throughout a walking bout, contrary to traditional linear measures that treat each as independent to the last (11,49,83). These measures represent the smoothness, regularity, stability, variability, complexity and symmetry of gait, showing sensitivity delineating between pathological and healthy subjects (96-98) equal, or superior to the sensitivity of linear measures (99). Similarly, autocorrelation measures of regularity and symmetry represent a clinically relevant (31,44,67), dynamic substitute for spatio-temporal variability and symmetry respectively (36,94). Other measures, including harmonic ratio (HR) based on Fourier analysis and the root-mean square (RMS) of acceleration magnitudes, are clinically relevant indicators of the smoothness, rhythmicity and symmetry of gait (33,100-102).

# **Methods**

### Literature Search

The PRISMA guidelines were followed for this systematic review (103) utilizing the following databases: PubMed; MEDLINE; EMBASE; Cochrane. Firstly, key search terms "gait" AND "accelerometer or inertial" were used to locate studies using inertial sensors to monitor gait. Next, "spatiotemporal" or "temporal" or "phase" or "stride" or "length" or "velocity" were used to locate publications that measure clinically relevant gait metrics beyond stepcount and activity. Finally, the terms "clinical or valid or validity or test or reference or standard" were included to reflect studies that had tested the validity of these wearable technologies or applied them clinically. Relevant MeSH (Medical Subject Heading) terms, variations and synonyms were adjusted for each database.

### Study selection

Studies from the above databases were collated and duplicate studies removed. Primary screening by an independent reviewer (JP) was performed based on the title and abstract of the remaining studies following the developed inclusion and exclusion criteria detailed below. Subsequent eligibility assessment was performed based on the full texts of remaining articles by an independent reviewer (JP) following the inclusion and exclusion criteria.

# Inclusion criteria

- (I) Articles involving wearable technology/ies.
- (II) The wearable technology features an inertial sensor (accelerometer, gyroscope) or is an IMU.
- (III) The wearable technology is a single-point sensor.
- (IV) Articles written in English.
- (V) Journal papers.

# Page 6 of 27

### Exclusion criteria

- (I) Wearable technology/ies only capable of identifying activity or step count.
- (II) Wearable technology/ies features multiple sensor points.
- (III) Wearable technology/ies classed as robotic or exoskeletons.
- (IV) Systematic reviews, books, or conference papers.

# Data collection

Following final article selection, results were classified as validation, clinical application or both. Data for validation studies was collected including sensor type(s); sensor placement; study aim(s); conclusions of study; primary gait metrics and methods. Critical analysis of validation studies was also included. Data collected for clinical applications studies included: sensor type(s); sensor placement; primary gait metrics and methods; and clinical application.

### **Bias** analysis

Three different tools were used for risk of bias assessment based on the nature of the studies. Validation and reliability studies were assessed using the Scottish Intercollegiate Guidelines Network (SIGN) methodology checklist for diagnostic tests (104,105). Of the clinical application studies, observational studies were assessed using the Newcastle-Ottawa Scale (106) while randomized-controlled trials (RCTs) were assessed using the SIGN checklist for RCTs (105,107). Case series and case reports were excluded from the use of these bias assessment scales as questions pertaining to comparability no longer apply. Studies were assessed by 3 independent reviewers (WJC), (SMR) and (MM) with at least 2 different reviewers for each study. Discrepancies in assessment were resolved by discussion and reaching a consensus.

### **Results**

From the 1,068 articles retrieved after duplicate removal, 90 articles were selected for inclusion (*Figure 1*). Thirty-two articles assessed the validity of single-point sensors and 48 used single-point sensor gait metrics analysis for clinical applications. Ten articles concurrently assessed validity and employed the device in a clinical application.

### Validity of single-point sensors

Among the 42 articles (*Figure 2*), 30 studies utilized trunkbased sensor methods; while 12 studies used alternate locations for the sensor placement which include four studies at the subjects' ear; two at the subjects' shank, two at the subjects' foot, one at the waist; while three other studies utilized smart devices with inertial sensors. The parameters used for validating the sensors include: HS, stride length/duration/regularity, SL/count/duration/ length variability/variability/time asymmetry/cycle time/ regularity/frequency, GV, cadence, traversed distance, walking time, stance duration, swing duration, single/ double support duration, HR, TO and time averaged acceleration.

# Validation studies by subject cobort

Among the 42 studies, 59 different cohort of patient population were studied (*Figure 3*). Twenty-five studies involved healthy adults, 11 studies involved elderly subjects, seven studies involved patients with PD, four studies in post-stroke patients with ataxia and three studies in Huntington's Disease (HD). There were two studies each for patients with lower limb amputees and diabetic patients. The remainders were single studies in subjects comprising healthy children, multiple sclerosis (MS) patients, orthopedic patients, muscular dystrophy patients, and patients suffering from motor neuron disease (Table S1).

# Clinical application of single-point IMUs

Fifty-eight articles discussed the use of single-point IMUs in clinical setting. Of these, 12 articles discussed the application of sensors in diagnosis and assessing severity of diseases (PD, MS, PN, Alzheimer's disease, age-related changes, frailty and foot & ankle health); 12 studies applied the sensors in monitoring rehabilitation and intervention efficacy (orthopedic, neurosurgical and oncological patients, foot orthoses, medical and physical intervention in neurodegenerative diseases); and 31 studies used sensors to characterize patients with different conditions from healthy subjects. Three articles described both diagnosis and severity of assessment as well as delineating healthy and participants with pathologies (*Table 2*, with more detailed findings of these articles in Tables S1,S2.



Figure 1 PRISMA methodology.



Number of studies validating single-point IMU gait analysis by sensor location

**Figure 2** Number of studies validating single-point IMU gait metrics analysis by sensor location. Smart devices have been attached on various locations, some separate to where they were designed to be worn – the iPod touch G4 (iOS 6, Apple Inc.) over L3 (108), the Apple Watch (Apple, San Francisco, CA, USA) on the wrist (4), and the Apple iPhone 5 (iPhone 5, Apple Inc., Cupertino, CA, USA) on the lateral waist (109). IMU, inertial measurement unit.

Distribution of validation studies by subject cohort



Figure 3 Distribution of validation studies by subject cohort.

### **Bias** assessment

Risk of bias assessment of validity studies did not reveal studies with an unacceptable level of bias. 31 studies were of high quality while nine were of acceptable quality in minimizing bias. The breakdown of the assessment and interpretation is included in Table S3. Areas in which many studies had 'unclear' levels of bias were in the patient selection domain criteria of selecting a consecutive sequence or random selection of participants. Understandably, many of these studies had small sample sizes and recruited volunteers or practiced convenience sampling of patients to achieve this. Many studies were able to reduce bias by conducting simultaneous testing of the IMU and reference standard. Criteria related to the use of a reference standard were not applied to reliability studies that did not use a reference test. The criteria related to pre-specified thresholds of the index test were also largely not applicable.

Of the clinical applicability studies, 30 were scored as "good" quality, eight as "fair" and 12 as "poor". Two RCTs were deemed having acceptable quality and one RCT as high quality in minimizing bias. The breakdown of the bias assessment results and interpretation is included in Appendix 1). Most studies generally missed out a score on ascertainment of outcome using a blind investigation. This may be attributed to a lack of investigators needed to separate carrying out the test and interpreting data. However, this was regarded as not having a large influence on overall bias assessment as measurements using IMUs are automatically recorded to software and not requiring direct human measurement. It would also be difficult to blind assessors to diseased patients with an obvious gait pathology to healthy controls. The RCTs also had unclear blinding of subjects and investigators to treatment groups. The strengths of these studies were the randomization process and standardization of testing and analysis between treatment and control groups.

### **Discussion**

In our review, single-point IMUs have been reasonably validated in the measurement of spatial and temporal gait parameters (85,86,124). However, IMUs have shown difficulty in estimating variability and asymmetry metrics (48,70,118,125-127). Alongside this, whilst IMUs have shown promise in their clinical applications, such as in the diagnosis of disease (31,32,47,53) and the assessment of treatment efficacy (56,113,128), these studies have predominantly relied on straight-line gait metrics. This critically limits external validity to free-living analysis where day-to-day movements typically represent more complex patterns of acceleration and deceleration. Moreover, studies focusing on clinical application have predominantly described obvious gait changes and have not necessarily demonstrated IMUs to be useful in evaluating subtle differences in gait patterns. Therefore, additional studies focusing on validation and clinical application are required before any mass clinical and commercial uptake of singlepoint wearable sensors can occur.

Table 2 Clinical applications of single point IMUs \_\_\_\_\_

Reference	Application
Diagnosis and severity assessment	PL 19 1
Demonceau <i>et al.</i> , 2015 (31)	Determine PD severity
Herman <i>et al.</i> , 2014 (57)	Classify PD subtypes
Dalton <i>et al.</i> , 2013 Collett <i>et al.</i> , 2014 Pau <i>et al.</i> , 2016 (47,62,110)	Determine MS severity
Esser <i>et al.</i> , 2018 (111)	Detect PN
De Bruin <i>et al.</i> , 2012 (53)	Determine PN severity
Gillain <i>et al.</i> , 2016 (39)	Predict risk of Alzheimer's development
Kosse <i>et al.</i> , 2016 Terrier <i>et al.</i> , 2015 (65,108)	Predict age-related gait change
Soangra <i>et al.</i> , 2018 Martinez-Ramirez <i>et al.</i> , 2015 (43,109)	Predict frailty status/determine severity
Van Schooten <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2017 (33,34)	Predict falls/determine falls risk
Angthong et al., 2018 (112)	Assessment of foot/ankle conditions
Rehabilitation and intervention efficacy	
Atallah <i>et al.,</i> 2014 Rapp <i>et al.,</i> 2015 (76,113)	Total hip and knee replacement efficacy and recovery
Jarchi <i>et al.</i> , 2016 (77)	Anterior cruciate ligament repair recovery
Mobbs <i>et al.</i> , 2018 (4)	Lumbar microdiscectomy recovery
Hojan <i>et al.</i> , 2014 (54)	Effect of breast prostheses after mastectomy
Mutoh <i>et al.</i> , 2016 Manikowska <i>et al.</i> , 2013 (5,56)	Hippotherapy efficacy in cerebral palsy
Henderson <i>et al.</i> , 2016 (114)	Rivastigmine efficacy in PD
Terrier <i>et al.</i> , 2009 (115)	Prescription footwear efficacy in foot/ankle fractures
Doi <i>et al.</i> , 2013 Pau <i>et al.</i> , 2014 Perrochon <i>et al.</i> , 2015 (38,60,101)	Improvement in gait after physical activity in elderly and cognitive impairment
Delineating pathological subjects from healthy controls	
Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Bolink <i>et al.</i> , 2012 (67,68,116)	Knee osteoarthritis subjects

Table 2 (continued)

### Page 10 of 27

Table 2 (continued)

Reference	Application
Lamoth <i>et al.</i> , 2010 Houdijk <i>et al.</i> , 2008 (48,49)	Amputee subjects
Terrier <i>et al.</i> , 2017 (74)	Chronic lower limb pain subjects
Arvin <i>et al.</i> , 2015 (58)	Hip abductor fatigue Subjects
Esser <i>et al.</i> , 2011 Mizuike <i>et al.</i> , 2009 Meijer <i>et al.</i> , 2011 (41,52,102)	Muscular dystrophy/Motor neuron disease/Stroke subjects
Hickey <i>et al.</i> , 2016 Matsushima <i>et al.</i> , 2015 (70, 117)	Ataxia disorder subjects
Demonceau <i>et al.</i> , 2015 Del Din <i>et al.</i> , 2016 Esser <i>et al.</i> , 2013 Hatanaka <i>et al.</i> , 2016 Yang <i>et al.</i> , 2011 (31,46,69,72,118)	PD/Progressive supranuclear palsy subjects
Pau <i>et al.</i> , 2017 Pau <i>et al.</i> , 2018 Storm <i>et al.</i> , 2018 (63,119,120)	MS subjects
Dalton <i>et al.</i> , 2013 Collett <i>et al.</i> , 2014 (47,110)	HD subjects
Manikowska <i>et al.</i> , 2013 (55)	Menopausal women
Tanigawa <i>et al.</i> , 2018 (121)	Pregnant patients with lumbopelvic pain
Iosa <i>et al.</i> , 2013 Saether <i>et al.</i> , 2014 (42,78)	Cerebral palsy subjects
Moe-Nilssen et al., 2003 (122)	Dyslexia subjects
Awotidebe et al., 2016 (61)	Type 2 diabetes subjects
Chung <i>et al.</i> , 2012 Maquet <i>et al.</i> , 2010 Martinez-Ramirez <i>et al.</i> , 2016 Lamoth <i>et al.</i> , 2011 (37,44,51,123)	Cognitively impaired subjects
Auvinet e <i>t al.</i> , 2003 Bautmans <i>et al.</i> , 2011 (36,50)	Falls risk/fallers

IMU, inertial measurement unit; PD, Parkinson's Disease; MS, multiple sclerosis; PN, peripheral neuropathy; HD, Huntington's Disease. Detailed findings of these articles can be found in Tables S1,S2.

### Validating IMU gait metrics analysis

Proposed methods and sensor locations for determination of gait metrics from single-point IMU acceleration data are generally validated against a standard or by test-retest reliability (129). The large portion of validation research employing lower trunk sensors compared with alternative sensor locations is reflected in *Figure 2*.

### Trunk-based sensor methods

Association of lower trunk accelerations with HS and TO, and the ability to predict these accelerations with an IP model of the body's center of mass (COM) trajectory, has prompted the proposal of several methods for GE and spatio-temporal parameter estimation from these signals.

# Methods by Zijlstra & Hof (86)

Peak detection and IP methods proposed by Zijlstra & Hof (86) utilizing a tri-axial accelerometer over the lower trunk demonstrated accurate detection of GEs and limited mean spatio-temporal parameters when compared to GRF from a treadmill. However, the straight-walking protocol employed limits external validity to daily-living analysis. Similarly, 100% of GEs were detected in only nine subjects of a small sample (n=15) of healthy adults, with 12% of GEs identified falsely in the remaining subjects. Furthermore, SL calculation which requires input of individual leglength was consistently underestimated before application of a 1.25 correction factor, revealing limitations in the model itself. Further validation in healthy adults has demonstrated accurate estimation of mean spatio-temporal parameters when compared to stereophotogrammetry and dynamometry, however significant differences were found for gait phase durations that rely on determining TO which isn't explicitly detected by the model (124). SL estimation was again detected with less accuracy due to errors implied by double-integration in this method (124). Further model limitations were identified in neurological populations (41) as neither a generic (1.25) or pathology-specific correction factor could be applied for accurate SL estimation, alluding to the need for individual corrections in pathological cohorts. This finding was reflected when validated in child (130) and older cohorts (131). The model has been further validated in small samples of PD subjects against motion capture (132), MS subjects against an instrumented walkway (110) and through test-retest reliability (47) for mean and variability spatio-temporal measures. These studies also assessed reliability of non-linear variability measures (47) and demonstrated feasibility of anterior

trunk sensor placement, representing an attenuated version of COM accelerations (110). Methods from Zijlstra and Hof (86) have been incorporated into commercially available IMUs, G-Walk (BTS, Milan, Italy) and DynaPort (McRoberts, The Hague, Netherlands). DynaPort accuracy has been assessed in children (130), lower-limb prosthesis (48), diabetes (53), healthy elderly (125,126) and falls risk subjects (50), while G-walk accuracy has been assessed in healthy adult (133-135), PD (136) and MS (137) subjects. Despite determining mean spatiotemporal parameters accurately in most studies, caution is recommended for interpretation of linear variability and asymmetry parameters (48,125,126). The interpretation of gait phase durations reliant on TO (stance, swing, single, double support time) is also uncertain since this event is not explicitly detected by the algorithm (133,136,137). Furthermore, testing limited to small samples in controlled straight-walking conditions limits power of inference to gait metrics analysis in pathological cohorts or scenarios of daily-living.

Autocorrelation methods utilizing lower trunk accelerations from a tri-axial accelerometer (94) have demonstrated test-retest reliability in a small sample (n=20) of healthy subjects for RMS and mean spatiotemporal parameter assessment (138) in straight-walking protocols. Despite lacking further validation for traditional spatio-temporal parameters, the test-retest reliability of autocorrelation measures of regularity and symmetry have been demonstrated in small samples of elderly, falls-risk and HD subjects in straight-walking protocols (47,50,139).

# Methods by McCamley et al. (85)

CWT for GE detection and IP methods for spatial parameter estimation proposed by McCamley et al. (85) using a lower trunk IMU have been validated against stereophotogrammetry and force plates. It has also been compared against previous methods from Zijlstra & Hof (86) and González et al. (87). Despite limitations of a small sample (n=18) of healthy subjects and a straightwalking protocol of only 3.6 m, the method by McCamley et al. (85) provided an improved estimate of SL and GE detection compared to previous methods. Validity for temporal parameter means and variability has been subsequently demonstrated in both controlled and freeliving conditions against pressure insoles, despite observed accuracy decreases in free-living conditions (140). Similar protocols in MS patients validated measurement of mean temporal parameters (120). However, variability measures were highly overestimated, with inaccuracies increasing

### Page 12 of 27

with length of walking bout, detracting from applicability to continuous monitoring. The lower accuracy for which this method detects TO compared to HS, may account for difficulty estimating variability measures, shown to be highly sensitive to incorrect GE identification compared to mean parameters (120). Method accuracy was also shown to be speed-dependent and decrease with increasing disability, hindering reliability in pathological cohorts (120).

# Method by Godfrey et al. (95,141) combining those by Zijlstra & Hof (86) and McCamley et al. (85)

Combining methods by McCamley et al. (85) for temporal parameter and Zijlstra & Hof (86) for SL estimation, Godfrey et al. (95,141) demonstrated validity against an instrumented walkway and through test-retest reliability in large populations of young and older adults (cumulative n=92) in protocols reflecting daily-living. Despite acceptable agreement for mean spatio-temporal parameters, SL underestimation was again attributed to limitations with generic correction factors, straight-walking dependent IP model and mathematical integration errors. Both methods' measures of spatio-temporal variability and asymmetry were poor, concurring with findings of other studies using an instrumented walkway as a control (70,125-127). In defense of IMUs, Godfrey et al. (95) demonstrated that discrepancies in variability and asymmetry were due to inherent differences between IMUs and instrumented walkways used in these studies, rather than IMU inaccuracy. This highlights the importance of caution when choosing a standard for validation purposes. Demonstrated discriminatory power between pathological and healthy cohorts based on IMU asymmetry and variability measures, despite poor agreement with an instrumented walkway, reinforces these conclusions (70).

# Other methods of GE and spatio-temporal parameter estimation

Waist-placed sensor and algorithm development has also been validated. Direct integration methods for SL estimation based on a waist placed IMU (88) were validated against stereophotogrammetry. However, limited gait parameters, a small sample (n=9) of healthy patients and accuracy discrepancies between left and right steps due to anatomically asymmetrical sensor placement limit clinical applicability (88).

To combat the plethora of COM methods, a comparison of five methods (85,86,88,89,142) against stereophotogrammetry and force plates for determination of temporal parameters was conducted by Trojaniello *et al.* (143). The different GE identification methods

incorporated largely either the zero-crossing or waveletbased method. Zjilstra & Hof (86) used a zero-crossing method where foot contact was taken as peak forward acceleration preceding the change of sign of acceleration from positive to negative. González et al. also used a zerocrossing method to approximate a search window prior to applying certain heuristic rules to determine the peak associated with the contact event (142). In conjunction with the zero-crossing method, Shin et al. used a sliding window summing technique to reduce noise (89). The method by McCamley et al. involved integrating and differentiating the acceleration signal using Gaussian continuous wavelet transforms prior to identifying initial and final contact events from the minima and maxima of the smoothed signal (85). Köse et al. used a wavelet-based method to identify windows of interest prior to decomposition and reconstruction of the original signal based on certain threshold application. Heel strike was then detected as the timepoint between signals of the different local frame axes (88). No statistically significant difference was found between methods for stride and step duration and the standard. However, methods that detect TO in addition to HS to allow determination of gait phase durations (85,87,88) showed a statistically significant difference, due to difficulties detecting the smoother acceleration signals indicating TO (143). Omitting assessment of spatial parameter methods limits completeness of the study. While despite examining a large sample, comparison of methods in healthy controls limits external validity to pathological cohorts. In response, assessment of the three best-performing methods (85,86,89) in 10 hemiparetic, 10 PD and 10 HD subjects against an instrumented walkway was undertaken (144). This revealed a universal decrease in GE detection and temporal parameter accuracy compared to healthy subjects. However, no statistically significant differences were revealed regarding accuracy between IMU methods in any cohort, apart from PD subjects for which methods from Zijlstra & Hof (86) outperformed.

New methods are continuously being formulated for lower trunk IMU analysis of spatial and temporal parameters. Oyake *et al.* (145) recently proposed a new algorithm for SL symmetry determination, validated in stroke subjects, while Sejdić *et al.* (146) validated novel methods against motion capture data in PD and peripheral neuropathy (PN) subjects.

# Alternative sensor placements

Despite trunk IMUs maintaining the lion's-share of

research, methods based on alternative sensor positions have also garnered validation attention.

An ear-worn tri-axial accelerometer has been validated in healthy and lower-limb orthopedic subjects against an instrumented treadmill for estimation of mean step time and symmetry (76). A similar sensor has also been validated for the detection of GE's and limited gait parameters in small samples of healthy (147), PD (148) and orthopedic (77) subjects in laboratory conditions.

With placement closer to the ground allowing better GE detection, sensors on the lower limb have also been proposed and validated. GV estimation from a single shank IMU was validated on a treadmill across numerous speeds and slope gradients (90). However, decrease in effectiveness of vertical shank inclination as a ZUPT re-calibration and subsequent GV accuracy with changing incline limits dailyliving application. Magbool et al. (149) further validated an algorithm for detection of GEs across walking speeds and slopes in eight healthy and two amputee subjects using a shank gyroscope. Straight-walking protocols and need for the instrumented shank to take the first step limit these studies' clinical applicability. IP methods using one foot IMU have been validated against a treadmill for GV estimation in five healthy subjects (91). However, difficult attachment of the IMU to the shoe, straight-walking protocols and an accuracy decrease with increasing incline limit applicability. Temporal parameter detection has also been validated using a foot IMU in eight healthy adults (92), showing strong correlation with motion capture. Limited validation of comprehensive gait metrics and inability to assess asymmetry and complex trunk-accelerometer measures with lower-limb sensor placement limits clinical applicability (88).

### Smart device gait analysis

Smart devices embedded with inertial sensors have become ubiquitous in everyday life, making them an obvious solution for maximizing patient compliance and allowing inconspicuous, portable gait analysis.

Initial proof of concept using an iPhone attached to the lateral malleolus demonstrated test-retest reliability for quantification of time averaged acceleration and step duration (150). However, unrealistic device placement, limited gait parameters and a sample of only one healthy patient limit validity and clinical applicability. Following this, utilizing trunk-based methods for GE detection (85-87) and SL estimation (86), high correlations were found for an iPhone against stereophotogrammetry for the identification of GE and mean spatio-temporal parameters in eleven healthy subjects (151). However, similar unrealistic device placement over the lumbar spine and waist has limited applicability to daily living. Addressing this, the reliability of smartphone locations: body, belt, bag, pocket and hand and validity against an instrumented walkway has been tested (152). Hand positions demonstrated poor reliability and agreement with the standard at slow speeds which only marginally improved at higher velocity, while high validity and excellent reliability were demonstrated in body, bag or belt positions at fast/comfortable speeds, lending traction to their incorporation into everyday gait monitoring. However, universal inaccuracies assessing gait at slow speeds limits application to pathological groups. Furthermore, limited emulation of free-living scenarios was employed with only five to nine steps investigated per trial (152).

# Validation status of single-point IMUs

Despite lacking validation for a comprehensive set of gait metrics in alternative positions, current COM systems are a proven alternative for calculation of a range of traditional spatio-temporal measures. However, these algorithms still need development, with caution recommended with interpretation of spatio-temporal variability and symmetry parameters, measures of gait phases and estimation of spatial parameters. Further validation is required in larger samples of pathological groups; Furthermore, their accuracy for continuous monitoring in scenarios of daily living needs to be assessed. Incorporation of these algorithms into commercial devices and smart devices is promising for clinical practicality and uptake.

# Clinical applications

Although the vision of single-point IMUs for gait metrics analysis in daily-living is in its infancy (4,34,69,120), these devices have been employed extensively in clinical environments to aid diagnosis and severity assessment, determine rehabilitation and intervention efficacy, and delineate pathological groups from healthy controls (*Table 2*). Of these applications, trunk-based IMUs are uniformly employed with the exception of a limited number of studies utilizing ear (76,77), foot (112,123) and smartdevice (4,108,109) analysis.

### Diagnosis and severity assessment

Single-point IMU gait metrics analysis has been employed as a method of assessment of ageing, orthopedic and neurological conditions.

Gait metrics analysis with single-point devices has aided diagnosis and severity assessment in numerous neurological diseases. Lower trunk sensor gait metrics analysis has been used to determine PD severity, demonstrating significantly reduced gait regularity and GV with increasing Hoeh and Yahr stage severity (31,32). Utilizing the commercially available DynaPort, Herman et al. (57) have also classified PD subtypes based on increased gait impairment and demonstrated classification superiority based on objective gait measures compared to conventional schemes. In MS, mean spatio-temporal parameter changes have been correlated with increasing disease severity using a G-Walk sensor, while also demonstrating high correlations between gait characteristics and patient-reported outcomes, reinforcing the applicability of gait metrics analysis as a clinical measure (62). Dalton et al. (110) also demonstrated significant differences between MS severity groups based on spatio-temporal mean and variability parameters as well as autocorrelation regularity and symmetry. Determining HD severity from trunk-based gait metrics analysis has also shown to correlate with clinical scales using both linear and non-linear measures (47). In diabetes subjects, gait parameters from a trunk IMU have shown good discriminatory power in detecting those with PN in a pilot study with a small sample (111), while De Bruin et al. (53) demonstrated the discriminatory power of SL to discern PN severity in type 2 diabetes patients in free-living gait conditions.

Similarly, gait metrics analysis has aided assessment in orthopedic conditions. Using a foot IMU, Angthong & Veljkovic (112) demonstrated significant correlations between obtained spatio-temporal parameters and subjective validated patient-reported outcomes and quality of life scores in patients with foot and ankle conditions such as arthritis, injury and tendinopathy. This is suggestive of the validity of gait assessment in clinical practice as an objective outcome measure.

In cognitive impairment, analysis of mean spatiotemporal and autocorrelation measures using a trunk IMU has been shown to predict risk of decline from mild cognitive impairment (MCI) to Alzheimer's Disease in small sample sizes (n=23) (39). Furthermore, single-point gait quantification has been used to delineate between dementia subtypes (153).

Decline in physical and cognitive capacity with age is associated with frailty and disability, with consequences including falls, hospitalization and death. Numerous studies using single-point sensors and smart-devices have attempted to predict age-related gait changes (65,108), predict frailty status and determine severity (43,109) and predict falls and determine risk (33,34) to allow early-intervention to reduce adverse outcomes.

### Rehabilitation and intervention efficacy

Gait metrics analysis using single-point IMUs has been used as an objective measure of rehabilitation and intervention efficacy in a range of conditions.

Single-point IMUs have been employed in the assessment of surgical outcomes and rehabilitation. A range of objective gait measures from trunk IMUs have been obtained to determine operation efficacy and rehabilitation progress after total hip replacement (113) and decompressive laminectomy for lumbar spine stenosis (128). An ear-worn sensor has been used to evaluate recovery from anterior cruciate ligament repair based on gait symmetry (147) as well as total hip and knee replacements based on stride duration and gait symmetry in small samples (76). Similarly, employment of the consumer available Apple Watch (Apple, San Francisco, CA, USA) for detection of GV was claimed invaluable in monitoring recovery through continuous gait monitoring in daily life following lumbar microdiscectomy in a single patient (4).

Assessment of non-operable intervention efficacy has also been determined using trunk IMUs. In cerebral palsy subjects, improvement in spatio-temporal mean and symmetry parameters after one hippotherapy session (56) and increase in mean parameters over a twoyear intervention course (5) has been demonstrated. While linear measures of gait variability from trunk accelerations have been used to determine the effectiveness of Rivastigmine in in PD subjects over 32 weeks (114). In orthopedics, the effectiveness of prescription footwear has been assessed through trunk-based autocorrelation gait metrics analysis in severe foot and ankle fractures (115). While in women following single-breast mastectomy, significant influence of external breast prosthesis on spatiotemporal parameters of gait has been demonstrated (54).

Prescribed physical activity programs have been shown to improve physical functioning and reduce risk of falls and adverse outcomes (154). Pau *et al.* (60) utilized a trunk accelerometer to determine the increased effectiveness of vigorous compared to light physical activity on mean spatiotemporal parameters in elderly over 36 weeks. Similarly, the positive effect of PA on a range of spatio-temporal and accelerometer-based measures was demonstrated in MCI (101) and dementia subjects (38) using trunk-based

### accelerometry.

The efficacy of neurorehabilitation has also been assessed using trunk-based gait analysis. Santoyo *et al.* (155) demonstrated an increase in mean spatio-temporal parameters following a five-month neurorehabilitation program in 45 MS patients. Furthermore, Zanetta et al. (156) demonstrated similar improvements in cadence and GV after a four-week program, and significant correlation of gait parameters with validated clinical assessments (Berg Balance Scale, 6MWT), validating the usefulness of gait metrics analysis as an objective measure of outcomes.

### Delineating pathological and healthy subjects

Most single-point IMU clinical applications focus on delineating between pathological groups with gait impairments and healthy controls. This application enables clinical validation of gait metrics and appreciation of metrics relevant to different pathologies.

Quantification of gait through single-point sensors in musculoskeletal disorders has been assessed. Knee osteoarthritis patients have been delineated from healthy controls based on numerous mean, autocorrelation and accelerometer-based spatio-temporal measures (67,68,116). In amputee gait, measures of stability, regularity and variability (49) as well as mean spatio-temporal parameters (48) have shown significant difference from healthy controls. Hip adductor fatigue has been demonstrated to significantly impact variability and symmetry of gait (58), while patients with chronic lower limb pain have demonstrated significant differences in cadence, variability and symmetry measures compared to controls (74). Using a trunk IMU in pregnant patients, significant differences have also been noted in trunk movement asymmetries between those with and without lumbopelvic pain. (121)

Numerous neurological conditions show altered gait quality using single-point IMUs. In stroke, RMS, autocorrelation measures of regularity and symmetry (102) and GV (52) have shown significant differences compared to controls. The gait impairments of various ataxia disorders have been assessed, demonstrating significant differences in mean, variability and asymmetry of spatiotemporal characteristics as well as autocorrelation and accelerometer-based measures (70,117). In PD, Esser *et al.* (46) demonstrated superior sensitivity of GV and nonlinear variability measures compared to mean parameters for delineation from healthy controls in a small sample (n=24). Further works have demonstrated the ability of mean and symmetry spatio-temporal parameters as well as autocorrelation measures in both laboratory and freeliving gait to delineate between PD subjects and healthy controls (31,69,72,118). Accelerometer-based measures of gait smoothness (HR) have also been shown to delineate between MS and healthy subjects prior to any measurable changes in mean spatio-temporal parameters (119), while dual-task gait in these patients has shown to result in a significant difference in mean spatio-temporal parameters compared to controls (63). In HD, significant differences have been demonstrated for autocorrelation measures, mean spatio-temporal parameters and both linear and nonlinear variability measures against healthy subjects (47,110). Furthermore, in type 2 diabetes (61) and normal pressure hydrocephalus (157), altered spatio-temporal parameters have been demonstrated compared to healthy controls. In child pathological cohorts, differences in gait parameters have also been demonstrated in cerebral palsy (42,78) and dyslexia subjects (122) compared to healthy controls.

The effect of cognitive impairment on gait has also been quantified compared to healthy controls using singlepoint sensors (37,52,123,153). Gait differences have been quantified in those at risk or with a history of falls, with autocorrelation measures of regularity and symmetry, GV, stride length and step-time asymmetry showing significant discriminative capacity against healthy controls (36,50).

Limitation of single-point IMUs in delineating diseases Clinical use of IMUs discussed above were mainly describing an obvious gait change (e.g., MS or Parkinson disease) rather than minute structural damages such as a torn hip labrum. Therefore, current use of a single-point IMU has to be considered within the appropriate clinical context. Additionally, the clinical application studies included are largely limited to straight line gait metrics assessment which does not fully reflect real-life movements. Along with the maturation of single-point IMUs in terms of validity, future studies should attempt to assess validity of these sensors in picking up complex movements that reflect real life movements such as falls.

### Future prospects

The ability for wearable devices in detecting gait and posture is maturing and undergoing continuous development. Multiple studies have demonstrated the use of wearable technologies in aiding postural analysis as well as serving as a tool for the general population in everyday postural/activity tracking (158,159). A novel scoring algorithm incorporating gait and postural scores has also been proposed to report patients' outcome in a manner which is simple and conducive to a continuous stream of data that can be remotely monitored by clinicians (160). This ability to remotely measure and record continuous data gives wearable devices an upper hand compared to lab-based instruments which are geographically sparse and perform gait analysis at discrete time points, though validity and standardization remains a drawback currently (4,23,158-160).

Future studies are required before the implementation of IMUs can be recommended to clinicians. In particular, there is an urgent need to validate IMU accuracy in free-living home environments, with most current validation studies instead measuring gait metrics on straight-line pathways. Other parameters such as U-turns, complex acceleration and deceleration that mimics day-to-day movements such as slowing down when approaching a door or chair could be studied. In addition, single-point IMUs have not been consistently shown to have high accuracy when measuring variability and asymmetry metrics. Future studies may assess other models for GE detection, which are continuously being developed, that may more accurately capture these metrics. Moreover, many of the studies focusing on clinical application have described obvious gait changes. While IMUs are still useful in objectively quantifying these changes, more evidence is required to demonstrate the clinical applications of IMUs in the measurement of subtle gait differences. Future studies to compare user acceptability and compliance between single-point IMUs and multipoint IMUs should also be conducted. Studies to determine ideal placement location of single-point IMUs at various body parts could also be conducted. Further developments and validation may one day bridge the gap for incorporating wearable technologies into actual clinical setting in aiding diagnosis and monitoring patient progression.

# Conclusions

This review has demonstrated the validity of single-point IMUs as an alternative to current quantitative methods and their ability to assist in clinical scenarios. The accuracy of these systems for detection of traditional metrics as well as the demonstrated clinical relevance of novel, accelerometerbased measures is promising for practicality and efficacy in the clinical context. Further validation for long-term, continuous monitoring in daily living scenarios is required as is performance in larger samples of pathological cohorts before mass commercial and clinical uptake can be expected.

# **Acknowledgments**

Funding: None.

# Footnote

*Reporting Checklist:* The authors have completed the PRISMA reporting checklist. Available at https://dx.doi. org/10.21037/mhealth-21-17

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi. org/10.21037/mhealth-21-17). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

### References

- Cook RE, Schneider I, Hazlewood ME, et al. Gait analysis alters decision-making in cerebral palsy. J Pediatr Orthop 2003;23:292-5.
- Hodgins A, Manning O, Ritsma B, et al. Validity of Wearable Sensors in Measuring Gait Quality Following Stroke. World Stroke Congress 2018.
- Lecat M, Decavel P, Magnin E, et al. Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review. Eur Neurol 2017;78:272-86.
- Mobbs RJ, Katsinas CJ, Choy WJ, et al. Objective monitoring of activity and Gait Velocity using wearable accelerometer following lumbar microdiscectomy to detect recurrent disc herniation. J Spine Surg 2018;4:792-7.

- Mutoh T, Mutoh T, Takada M, et al. Application of a triaxial accelerometry-based portable motion recorder for the quantitative assessment of hippotherapy in children and adolescents with cerebral palsy. J Phys Ther Sci 2016;28:2970-4.
- Steultjens MP, Dekker J, van Baar ME, et al. Range of joint motion and disability in patients with osteoarthritis of the knee or hip. Rheumatology (Oxford) 2000;39:955-61.
- Tzallas AT, Tsipouras MG, Rigas G, et al. PERFORM: a system for monitoring, assessment and management of patients with Parkinson's disease. Sensors (Basel) 2014;14:21329-57.
- Zhang HH, Yan SH, Fang C, et al. Clinical Evaluation and Gait Characteristics before and after Total Knee Arthroplasty Based on a Portable Gait Analyzer. Orthop Surg 2016;8:360-6.
- 9. Verghese J, Holtzer R, Lipton RB, et al. Quantitative gait markers and incident fall risk in older adults. J Gerontol A Biol Sci Med Sci 2009;64:896-901.
- Schwenk M, Mohler J, Wendel C, et al. Wearable sensorbased in-home assessment of gait, balance, and physical activity for discrimination of frailty status: baseline results of the Arizona frailty cohort study. Gerontology 2015;61:258-67.
- Chen S, Lach J, Lo B, et al. Toward Pervasive Gait Analysis With Wearable Sensors: A Systematic Review. IEEE J Biomed Health Inform 2016;20:1521-37.
- Saleh M, Murdoch G. In defence of gait analysis. Observation and measurement in gait assessment. J Bone Joint Surg Br 1985;67:237-41.
- Cappozzo A, Della Croce U, Leardini A, et al. Human movement analysis using stereophotogrammetry. Part 1: theoretical background. Gait Posture 2005;21:186-96.
- Spine News International. Wearables in spine surgery: Beginnings, research and real-world applications 2017. Available online: https://spinalnewsinternational.com/ wearables/
- Rehan K. Wearing Your Spine Health on Your Sleeve Spine Universe. 2017. Available online: https://www. spineuniverse.com/treatments/emerging/wearing-yourspine-health-your-sleeve
- Mobbs RJ, Phan K, Maharaj M, et al. Physical Activity Measured with Accelerometer and Self-Rated Disability in Lumbar Spine Surgery: A Prospective Study. Global Spine J 2016;6:459-64.
- Phan K, Mobbs RJ. Long-Term Objective Physical Activity Measurements using a Wireless Accelerometer Following Minimally Invasive Transforminal Interbody

Fusion Surgery. Asian Spine J 2016;10:366-9.

- Agostini V, Gastaldi L, Rosso V, et al. A Wearable Magneto-Inertial System for Gait Analysis (H-Gait): Validation on Normal Weight and Overweight/Obese Young Healthy Adults. Sensors (Basel) 2017;17:2406.
- Donath L, Faude O, Lichtenstein E, et al. Mobile inertial sensor based gait analysis: Validity and reliability of spatiotemporal gait characteristics in healthy seniors. Gait Posture 2016;49:371-4.
- 20. Kluge F, Gaßner H, Hannink J, et al. Towards Mobile Gait Analysis: Concurrent Validity and Test-Retest Reliability of an Inertial Measurement System for the Assessment of Spatio-Temporal Gait Parameters. Sensors (Basel) 2017;17:1522.
- 21. Maffuletti NA, Gorelick M, Kramers-de Quervain I, et al. Concurrent validity and intrasession reliability of the IDEEA accelerometry system for the quantification of spatiotemporal gait parameters. Gait Posture 2008;27:160-3.
- Orlowski K, Eckardt F, Herold F, et al. Examination of the reliability of an inertial sensor-based gait analysis system. Biomed Tech (Berl) 2017;62:615-22.
- Rao PJ, Phan K, Maharaj MM, et al. Accelerometers for objective evaluation of physical activity following spine surgery. J Clin Neurosci 2016;26:14-8.
- Barth J, Klucken J, Kugler P, et al. Biometric and mobile gait analysis for early diagnosis and therapy monitoring in Parkinson's disease. Annu Int Conf IEEE Eng Med Biol Soc 2011;2011:868-71.
- Guo Y, Wu D, Liu G, et al. A low-cost body inertialsensing network for practical gait discrimination of hemiplegia patients. Telemed J E Health 2012;18:748-54.
- 26. Hsu YL, Chung PC, Wang WH, et al. Gait and balance analysis for patients with Alzheimer's disease using an inertial-sensor-based wearable instrument. IEEE J Biomed Health Inform 2014;18:1822-30.
- 27. Mackey AH, Stott NS, Walt SE. Reliability and validity of an activity monitor (IDEEA) in the determination of temporal-spatial gait parameters in individuals with cerebral palsy. Gait Posture 2008;28:634-9.
- Tadano S, Takeda R, Sasaki K, et al. Gait characterization for osteoarthritis patients using wearable gait sensors (H-Gait systems). J Biomech 2016;49:684-90.
- Tunca C, Pehlivan N, Ak N, et al. Inertial Sensor-Based Robust Gait Analysis in Non-Hospital Settings for Neurological Disorders. Sensors (Basel) 2017;17:825.
- Sprager S, Juric MB. Inertial Sensor-Based Gait Recognition: A Review. Sensors (Basel) 2015;15:22089-127.

# Page 18 of 27

- 31. Demonceau M, Donneau AF, Croisier JL, et al. Contribution of a Trunk Accelerometer System to the Characterization of Gait in Patients With Mild-to-Moderate Parkinson's Disease. IEEE J Biomed Health Inform 2015;19:1803-8.
- Cheng JZ, Von Coelln R, Schrader K, et al. Accelerometry-based quantitative analysis of mobility in Parkinson disease. Neurology 2018;90:P3.044.
- van Schooten KS, Pijnappels M, Rispens SM, et al. Daily-Life Gait Quality as Predictor of Falls in Older People: A 1-Year Prospective Cohort Study. PLoS One 2016;11:e0158623.
- 34. Del Din S, Galna B, Godfrey A, et al. Analysis of Free-Living Gait in Older Adults With and Without Parkinson's Disease and With and Without a History of Falls: Identifying Generic and Disease-Specific Characteristics. J Gerontol A Biol Sci Med Sci 2019;74:500-6.
- 35. Espinosa HG, Thiel DV, Sorell M, et al. Can We Trust Inertial and Heart Rate Sensor Data from an APPLE Watch Device? Proceedings 2020;49:128.
- 36. Auvinet B, Berrut G, Touzard C, et al. Gait abnormalities in elderly fallers. J Aging Phys Act 2003;11:40-52.
- Maquet D, Lekeu F, Warzee E, et al. Gait analysis in elderly adult patients with mild cognitive impairment and patients with mild Alzheimer's disease: simple versus dual task: a preliminary report. Clin Physiol Funct Imaging 2010;30:51-6.
- Perrochon A, Tchalla AE, Bonis J, et al. Effects of a Multicomponent Exercise Program on Spatiotemporal Gait Parameters, Risk of Falling and Physical Activity in Dementia Patients. Dement Geriatr Cogn Dis Extra 2015;5:350-60.
- Gillain S, Dramé M, Lekeu F, et al. Gait speed or gait variability, which one to use as a marker of risk to develop Alzheimer disease? A pilot study. Aging Clin Exp Res 2016;28:249-55.
- 40. Walking and running analysis gait analysis devices Paris: Centaure Metrix. [cited 2021 Jun 28]. Available online: http://www.centaure-metrix.com/Index\_en.html
- 41. Esser P, Dawes H, Collett J, et al. Assessment of spatiotemporal gait parameters using inertial measurement units in neurological populations. Gait Posture 2011;34:558-60.
- 42. Saether R, Helbostad JL, Adde L, et al. Gait characteristics in children and adolescents with cerebral palsy assessed with a trunk-worn accelerometer. Res Dev Disabil 2014;35:1773-81.
- 43. Martínez-Ramírez A, Martinikorena I, Gómez M, et al. Frailty assessment based on trunk kinematic parameters

during walking. J Neuroeng Rehabil 2015;12:48.

- Martínez-Ramírez A, Martinikorena I, Lecumberri P, et al. Dual Task Gait Performance in Frail Individuals with and without Mild Cognitive Impairment. Dement Geriatr Cogn Disord 2016;42:7-16.
- 45. MTi-1 IMU Enschede: Xsens. [cited 2021 Jun 28]. Available online: https://www.xsens.com/mti-1-imu
- Esser P, Dawes H, Collett J, et al. Insights into gait disorders: walking variability using phase plot analysis, Parkinson's disease. Gait Posture 2013;38:648-52.
- Collett J, Esser P, Khalil H, et al. Insights into gait disorders: walking variability using phase plot analysis, Huntington's disease. Gait Posture 2014;40:694-700.
- Houdijk H, Appelman FM, Van Velzen JM, et al. Validity of DynaPort GaitMonitor for assessment of spatiotemporal parameters in amputee gait. J Rehabil Res Dev 2008;45:1335-42.
- Lamoth CJ, Ainsworth E, Polomski W, et al. Variability and stability analysis of walking of transfemoral amputees. Med Eng Phys 2010;32:1009-14.
- Bautmans I, Jansen B, Van Keymolen B, et al. Reliability and clinical correlates of 3D-accelerometry based gait analysis outcomes according to age and fall-risk. Gait Posture 2011;33:366-72.
- 51. Lamoth CJ, van Deudekom FJ, van Campen JP, et al. Gait stability and variability measures show effects of impaired cognition and dual tasking in frail people. J Neuroeng Rehabil 2011;8:2.
- 52. Meijer R, Plotnik M, Zwaaftink EG, et al. Markedly impaired bilateral coordination of gait in post-stroke patients: Is this deficit distinct from asymmetry? A cohort study. J Neuroeng Rehabil 2011;8:23.
- 53. de Bruin ED, Hubli M, Hofer P, et al. Validity and reliability of accelerometer-based gait assessment in patients with diabetes on challenging surfaces. J Aging Res 2012;2012:954378.
- 54. Hojan K, Manikowska F, Molinska-Glura M, et al. The impact of an external breast prosthesis on the gait parameters of women after mastectomy. Cancer Nurs 2014;37:E30-6.
- 55. Manikowska F, Hojan K, Chen PJ, et al. The gait pattern in post-menopausal women. Pilot study. Ortop Traumatol Rehabil 2013;15:575-83.
- 56. Manikowska F, Jóźwiak M, Idzior M, et al. The effect of a hippotherapy session on spatiotemporal parameters of gait in children with cerebral palsy - pilot study. Ortop Traumatol Rehabil 2013;15:253-7.
- 57. Herman T, Weiss A, Brozgol M, et al. Gait and balance

in Parkinson's disease subtypes: objective measures and classification considerations. J Neurol 2014;261:2401-10.

- Arvin M, Hoozemans MJ, Burger BJ, et al. Effects of hip abductor muscle fatigue on gait control and hip position sense in healthy older adults. Gait Posture 2015;42:545-9.
- MoveMonitor The Hague: McRoberts. [cited 2021 Jun 28]. Available online: https://www.mcroberts.nl/products/ movemonitor/
- 60. Pau M, Leban B, Collu G, et al. Effect of light and vigorous physical activity on balance and gait of older adults. Arch Gerontol Geriatr 2014;59:568-73.
- 61. Awotidebe TO, Ativie RN, Oke KI, et al. Relationships among exercise capacity, dynamic balance and gait characteristics of Nigerian patients with type-2 diabetes: an indication for fall prevention. J Exerc Rehabil 2016;12:581-8.
- 62. Pau M, Caggiari S, Mura A, et al. Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure. Mult Scler Relat Disord 2016;10:187-91.
- Pau M, Corona F, Pilloni G, et al. Texting while walking differently alters gait patterns in people with multiple sclerosis and healthy individuals. Mult Scler Relat Disord 2018;19:129-33.
- G-Walk: Wearable system for the functional analysis of movement Milan: BTS Bioengineering. [cited 2021 Jun 28]. Available online: https://www.btsbioengineering.com/ products/g-walk-inertial-motion-system/
- 65. Terrier P, Reynard F. Effect of age on the variability and stability of gait: a cross-sectional treadmill study in healthy individuals between 20 and 69 years of age. Gait Posture 2015;41:170-4.
- 66. Compact and versatile wireless inertial measurement unit Lausanne: Gaitup. [cited 2021 Jun 28]. Available online: https://research.gaitup.com/physilog/
- Barden JM, Clermont CA, Kobsar D, et al. Accelerometer-Based Step Regularity Is Lower in Older Adults with Bilateral Knee Osteoarthritis. Front Hum Neurosci 2016;10:625.
- Clermont CA, Barden JM. Accelerometer-based determination of gait variability in older adults with knee osteoarthritis. Gait Posture 2016;50:126-30.
- 69. Del Din S, Godfrey A, Galna B, et al. Free-living gait characteristics in ageing and Parkinson's disease: impact of environment and ambulatory bout length. J Neuroeng Rehabil 2016;13:46.
- 70. Hickey A, Gunn E, Alcock L, et al. Validity of a wearable accelerometer to quantify gait in spinocerebellar ataxia

type 6. Physiol Meas 2016;37:N105-17.

- 71. AX3 York: Axivity. [cited 2021 Jun 28]. Available online: https://axivity.com/product/ax3
- 72. Hatanaka N, Sato K, Hishikawa N, et al. Comparative Gait Analysis in Progressive Supranuclear Palsy and Parkinson's Disease. Eur Neurol 2016;75:282-9.
- Edwardson CL, Winkler EAH, Bodicoat DH, et al. Considerations when using the activPAL monitor in fieldbased research with adult populations. J Sport Health Sci 2017;6:162-78.
- 74. Terrier P, Le Carre J, Connaissa ML, et al. Monitoring of Gait Quality in Patients With Chronic Pain of Lower Limbs. IEEE Trans Neural Syst Rehabil Eng 2017;25:1843-52.
- 75. ActiGraph wGT3X-BT. Pensacola: Actigraph. [cited 2021 Jun 28]. Available online: https://actigraphcorp.com/ actigraph-wgt3x-bt/
- Atallah L, Wiik A, Lo B, et al. Gait asymmetry detection in older adults using a light ear-worn sensor. Physiol Meas 2014;35:N29-40.
- 77. Jarchi D, Lo B, Wong C, et al. Gait Analysis From a Single Ear-Worn Sensor: Reliability and Clinical Evaluation for Orthopaedic Patients. IEEE Trans Neural Syst Rehabil Eng 2016;24:882-92.
- Iosa M, Morelli D, Marro T, et al. Ability and stability of running and walking in children with cerebral palsy. Neuropediatrics 2013;44:147-54.
- Potter MV, Ojeda LV, Perkins NC, et al. Effect of IMU Design on IMU-Derived Stride Metrics for Running. Sensors (Basel) 2019;19:2601.
- Felisberto F, Fdez-Riverola F, Pereira A. A ubiquitous and low-cost solution for movement monitoring and accident detection based on sensor fusion. Sensors (Basel) 2014;14:8961-83.
- 81. Perry J, Schoneberger B. Gait Analysis: Normal and Pathological Function. SLACK, 1992.
- 82. Lord S, Galna B, Verghese J, et al. Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J Gerontol A Biol Sci Med Sci 2013;68:820-7.
- Lord S, Galna B, Coleman S, et al. Mild depressive symptoms are associated with gait impairment in early Parkinson's disease. Mov Disord 2013;28:634-9.
- Beauchet O, Allali G, Sekhon H, et al. Guidelines for Assessment of Gait and Reference Values for Spatiotemporal Gait Parameters in Older Adults: The Biomathics and Canadian Gait Consortiums Initiative. Front Hum Neurosci 2017;11:353.

# Page 20 of 27

- 85. McCamley J, Donati M, Grimpampi E, et al. An enhanced estimate of initial contact and final contact instants of time using lower trunk inertial sensor data. Gait Posture 2012;36:316-8.
- Zijlstra W, Hof AL. Assessment of spatio-temporal gait parameters from trunk accelerations during human walking. Gait Posture 2003;18:1-10.
- González RC, Alvarez D, López AM, et al. Ambulatory estimation of mean step length during unconstrained walking by means of COG accelerometry. Comput Methods Biomech Biomed Engin 2009;12:721-6.
- 88. Köse A, Cereatti A, Della Croce U. Bilateral step length estimation using a single inertial measurement unit attached to the pelvis. J Neuroeng Rehabil 2012;9:9.
- Shin SH, Park CG. Adaptive step length estimation algorithm using optimal parameters and movement status awareness. Med Eng Phys 2011;33:1064-71.
- Li Q, Young M, Naing V, et al. Walking speed estimation using a shank-mounted inertial measurement unit. J Biomech 2010;43:1640-3.
- 91. Sabatini AM, Martelloni C, Scapellato S, et al. Assessment of walking features from foot inertial sensing. IEEE Trans Biomed Eng 2005;52:486-94.
- 92. Song M, Kim J. An Ambulatory Gait Monitoring System with Activity Classification and Gait Parameter Calculation Based on a Single Foot Inertial Sensor. IEEE Trans Biomed Eng 2018;65:885-93.
- Baroudi L, Newman MW, Jackson EA, et al. Estimating Walking Speed in the Wild. Front Sports Act Living 2020;2:583848.
- Moe-Nilssen R, Helbostad JL. Estimation of gait cycle characteristics by trunk accelerometry. J Biomech 2004;37:121-6.
- Godfrey A, Del Din S, Barry G, et al. Instrumenting gait with an accelerometer: a system and algorithm examination. Med Eng Phys 2015;37:400-7.
- Sekine M, Akay M, Tamura T, et al. Fractal dynamics of body motion in patients with Parkinson's disease. J Neural Eng 2004;1:8-15.
- 97. Akay M, Sekine M, Tamura T, et al. Fractal dynamics of body motion in post-stroke hemiplegic patients during walking. J Neural Eng 2004;1:111-6.
- Hausdorff JM. Gait dynamics in Parkinson's disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling. Chaos 2009;19:026113.
- 99. Rochester L, Chastin SF, Lord S, et al. Understanding the impact of deep brain stimulation on ambulatory activity in advanced Parkinson's disease. J Neurol 2012;259:1081-6.

- 100. Brach JS, McGurl D, Wert D, et al. Validation of a measure of smoothness of walking. J Gerontol A Biol Sci Med Sci 2011;66:136-41.
- 101. Doi T, Makizako H, Shimada H, et al. Effects of multicomponent exercise on spatial-temporal gait parameters among the elderly with amnestic mild cognitive impairment (aMCI): preliminary results from a randomized controlled trial (RCT). Arch Gerontol Geriatr 2013;56:104-8.
- 102. Mizuike C, Ohgi S, Morita S. Analysis of stroke patient walking dynamics using a tri-axial accelerometer. Gait Posture 2009;30:60-4.
- 103.Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
- 104. Scottish Intercollegiate Guidelines Network (SIGN).Methodology Checklist 5: Studies of Diagnostic Accuracy.2014. Available online: https://www.sign.ac.uk/what-we-do/methodology/checklists/
- 105.NHMRC. Guidelines for Guidelines: Assessing risk of bias. 2019. Available online: https://nhmrc.gov.au/ guidelinesforguidelines/develop/assessing-risk-bias
- 106. GA Wells, B Shea, D O'Connell, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 1999. Available online: http://www.ohri.ca/programs/clinical\_ epidemiology/oxford.asp
- 107. Scottish Intercollegiate Guidelines Network (SIGN). Methodology checklist 2: randomised controlled trials 2014. Available online: https://www.sign.ac.uk/what-wedo/methodology/checklists/
- 108. Kosse NM, Vuillerme N, Hortobágyi T, et al. Multiple gait parameters derived from iPod accelerometry predict age-related gait changes. Gait Posture 2016;46:112-7.
- 109. Soangra R, Lockhart TE. Inertial Sensor-Based Variables Are Indicators of Frailty and Adverse Post-Operative Outcomes in Cardiovascular Disease Patients. Sensors (Basel) 2018;18:1792.
- 110. Dalton A, Khalil H, Busse M, et al. Analysis of gait and balance through a single triaxial accelerometer in presymptomatic and symptomatic Huntington's disease. Gait Posture 2013;37:49-54.
- 111.Esser P, Collett J, Maynard K, et al. Single Sensor Gait Analysis to Detect Diabetic Peripheral Neuropathy: A Proof of Principle Study. Diabetes Metab J 2018;42:82-6.
- 112. Angthong C, Veljkovic A. Relationships among subjective patient-reported outcome, quality of life, and objective gait characteristics using wearable foot inertial-sensor

### Page 21 of 27

# mHealth, 2022

assessment in foot-ankle patients. Eur J Orthop Surg Traumatol 2019;29:683-7.

- 113.Rapp W, Brauner T, Weber L, et al. Improvement of walking speed and gait symmetry in older patients after hip arthroplasty: a prospective cohort study. BMC Musculoskelet Disord 2015;16:291.
- 114. Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Neurol 2016;15:249-58.
- 115. Terrier P, Dériaz O, Meichtry A, et al. Prescription footwear for severe injuries of foot and ankle: effect on regularity and symmetry of the gait assessed by trunk accelerometry. Gait Posture 2009;30:492-6.
- 116. Bolink SA, van Laarhoven SN, Lipperts M, et al. Inertial sensor motion analysis of gait, sit-stand transfers and stepup transfers: differentiating knee patients from healthy controls. Physiol Meas 2012;33:1947-58.
- 117. Matsushima A, Yoshida K, Genno H, et al. Clinical assessment of standing and gait in ataxic patients using a triaxial accelerometer. Cerebellum Ataxias 2015;2:9.
- 118. Yang CC, Hsu YL, Shih KS, et al. Real-time gait cycle parameter recognition using a wearable accelerometry system. Sensors (Basel) 2011;11:7314-26.
- 119. Pau M, Mandaresu S, Pilloni G, et al. Smoothness of gait detects early alterations of walking in persons with multiple sclerosis without disability. Gait Posture 2017;58:307-9.
- 120. Storm FA, Nair KPS, Clarke AJ, et al. Free-living and laboratory gait characteristics in patients with multiple sclerosis. PLoS One 2018;13:e0196463.
- 121. Tanigawa A, Morino S, Aoyama T, et al. Gait analysis of pregnant patients with lumbopelvic pain using inertial sensor. Gait Posture 2018;65:176-81.
- 122. Moe-Nilssen R, Helbostad JL, Talcott JB, et al. Balance and gait in children with dyslexia. Exp Brain Res 2003;150:237-44.
- 123. Chung P, Hsu Y, Wang C, et al. Gait analysis for patients with Alzheimer'S disease using a triaxial accelerometer. 2012 IEEE International Symposium on Circuits and Systems (ISCAS), 2012:1323-6.
- 124. Bugané F, Benedetti MG, Casadio G, et al. Estimation of spatial-temporal gait parameters in level walking based on a single accelerometer: validation on normal subjects by standard gait analysis. Comput Methods Programs Biomed 2012;108:129-37.
- 125.Hartmann A, Luzi S, Murer K, et al. Concurrent validity of a trunk tri-axial accelerometer system for gait analysis in older adults. Gait Posture 2009;29:444-8.

- 126.Hartmann A, Murer K, de Bie RA, et al. Reproducibility of spatio-temporal gait parameters under different conditions in older adults using a trunk tri-axial accelerometer system. Gait Posture 2009;30:351-5.
- 127.Byun S, Han JW, Kim TH, et al. Test-Retest Reliability and Concurrent Validity of a Single Tri-Axial Accelerometer-Based Gait Analysis in Older Adults with Normal Cognition. PLoS One 2016;11:e0158956.
- 128. Ohtaki Y, Mamizuka N, Hirano A, et al. Pre- and Postoperative Evaluations of Patients with Lumbar Spinal Stenosis by Clinical Walk Test Using an Inertial Sensor. Transactions of Japanese Society for Medical and Biological Engineering 2014;52:167-74.
- 129. Jarchi D, Pope J, Lee TKM, et al. A Review on Accelerometry-Based Gait Analysis and Emerging Clinical Applications. IEEE Rev Biomed Eng 2018;11:177-94.
- 130.Brandes M, Zijlstra W, Heikens S, et al. Accelerometry based assessment of gait parameters in children. Gait Posture 2006;24:482-6.
- 131.Zijlstra A, Zijlstra W. Trunk-acceleration based assessment of gait parameters in older persons: a comparison of reliability and validity of four inverted pendulum based estimations. Gait Posture 2013;38:940-4.
- 132. Esser P, Dawes H, Collett J, et al. Validity and inter-rater reliability of inertial gait measurements in Parkinson's disease: a pilot study. J Neurosci Methods 2012;205:177-81.
- 133.De Ridder R, Lebleu J, Willems T, et al. Concurrent Validity of a Commercial Wireless Trunk Triaxial Accelerometer System for Gait Analysis. J Sport Rehabil 2019;28:jsr.
- 134. Lim SY, Lee WH. Comparison of accelerometer-based and treadmill-based analysis systems for measuring gait parameters in healthy adults. J Phys Ther Sci 2017;29:651-3.
- 135.Park G; BHSc; Woo Y. Comparison between a center of mass and a foot pressure sensor system for measuring gait parameters in healthy adults. J Phys Ther Sci 2015;27:3199-202.
- 136.Zago M, Sforza C, Pacifici I, et al. Gait evaluation using inertial measurement units in subjects with Parkinson's disease. J Electromyogr Kinesiol 2018;42:44-8.
- 137. Gudesblatt M, Trebing S, Burke C, et al. Multiple sclerosis, gait and digital devices: A comparison of two FDA approved validated devices that provide multidimensional quantifiable gait parameters in people with multiple sclerosis (PWMS). Neurology Conference: 70th Annual Meeting of the American Academy of Neurology, AAN. 2018;90: P4.400.
- 138. Henriksen M, Lund H, Moe-Nilssen R, et al. Test-retest

# Page 22 of 27

reliability of trunk accelerometric gait analysis. Gait Posture 2004;19:288-97.

- 139. Grimpampi E, Oesen S, Halper B, et al. Reliability of gait variability assessment in older individuals during a sixminute walk test. J Biomech 2015;48:4185-9.
- 140. Storm FA, Buckley CJ, Mazzà C. Gait event detection in laboratory and real life settings: Accuracy of ankle and waist sensor based methods. Gait Posture 2016;50:42-6.
- 141. Godfrey A, Del Din S, Barry G, et al. Within trial validation and reliability of a single tri-axial accelerometer for gait assessment. Annu Int Conf IEEE Eng Med Biol Soc 2014;2014:5892-5.
- 142. González RC, López AM, Rodriguez-Uría J, et al. Realtime gait event detection for normal subjects from lower trunk accelerations. Gait Posture 2010;31:322-5.
- 143. Trojaniello D, Cereatti A, Della Croce U. Accuracy, sensitivity and robustness of five different methods for the estimation of gait temporal parameters using a single inertial sensor mounted on the lower trunk. Gait Posture 2014;40:487-92.
- 144. Trojaniello D, Ravaschio A, Hausdorff JM, et al. Comparative assessment of different methods for the estimation of gait temporal parameters using a single inertial sensor: application to elderly, post-stroke, Parkinson's disease and Huntington's disease subjects. Gait Posture 2015;42:310-6.
- 145. Oyake K, Yamaguchi T, Sugasawa M, et al. Validity of gait asymmetry estimation by using an accelerometer in individuals with hemiparetic stroke. J Phys Ther Sci 2017;29:307-11.
- 146. Sejdić E, Lowry KA, Bellanca J, et al. Extraction of stride events from gait accelerometry during treadmill walking. IEEE J Transl Eng Health Med 2016. doi: 10.1109/ JTEHM.2015.2504961.
- 147.Jarchi D, Lo B, Ieong E, et al. Validation of the e-AR Sensor for Gait Event Detection Using the Parotec Foot Insole with Application to Post-Operative Recovery Monitoring. 2014 11th International Conference on Wearable and Implantable Body Sensor Networks; 2014:127-31.
- 148. Jarchi D, Peters A, Lo B, et al. Assessment of the e-AR sensor for gait analysis of Parkinson;s Disease patients.
  2015 IEEE 12th International Conference on Wearable and Implantable Body Sensor Networks (BSN). 2015:1-6.
- 149. Maqbool HF, Husman MAB, Awad MI, et al. A Real-Time Gait Event Detection for Lower Limb Prosthesis Control and Evaluation. IEEE Trans Neural Syst Rehabil Eng 2017;25:1500-9.

- 150.Lemoyne R, Mastroianni T, Cozza M, et al. Implementation of an iPhone as a wireless accelerometer for quantifying gait characteristics. Annu Int Conf IEEE Eng Med Biol Soc 2010;2010:3847-51.
- 151.Pepa L, Verdini F, Spalazzi L. Gait parameter and event estimation using smartphones. Gait Posture 2017;57:217-23.
- 152. Silsupadol P, Teja K, Lugade V. Reliability and validity of a smartphone-based assessment of gait parameters across walking speed and smartphone locations: Body, bag, belt, hand, and pocket. Gait Posture 2017;58:516-22.
- 153.Ardle RM, Galna B, Thomas A, et al. Continuous Monitoring of Gait: What Can It Tell Us About Dementia? Alzheimer's and Dementia 2018;14:P192-3.
- 154. Suttanon P, Hill KD, Said CM, et al. Feasibility, safety and preliminary evidence of the effectiveness of a home-based exercise programme for older people with Alzheimer's disease: a pilot randomized controlled trial. Clin Rehabil 2013;27:427-38.
- 155. Santoyo C, Fabregas D, Janer M, et al. Changes in spatiotemporal gait parameters after physical rehabilitation in Multiple Sclerosis: A descriptive analysis. Mult Scler J 2018;24:866.
- 156.Zanetta C, Pisa M, Guerrieri S, et al. Intensive neurorehabilitation is associated with improved gait kinematic analysis in progressive multiple sclerosis. Mult Scler J 2017;23:144.
- 157.Ono Y, Ora H, Kiko Y, et al. Gait evaluation of normal pressure hydrocephalus using inertial sensor. J Neurol Sci 2017;381:722.
- 158. Chakravorty A, Mobbs RJ, Anderson DB, et al. The role of wearable devices and objective gait analysis for the assessment and monitoring of patients with lumbar spinal stenosis: systematic review. BMC Musculoskelet Disord 2019;20:288.
- 159. Yoong NKM, Perring J, Mobbs RJ. Commercial Postural Devices: A Review. Sensors (Basel) 2019;19:5128.
- 160. Simpson L, Maharaj MM, Mobbs RJ. The role of wearables in spinal posture analysis: a systematic review. BMC Musculoskelet Disord 2019;20:55.

### doi: 10.21037/mhealth-21-17

**Cite this article as:** Mobbs RJ, Perring J, Raj SM, Maharaj M, Yoong NKM, Sy LW, Fonseka RD, Natarajan P, Choy WJ. Gait metrics analysis utilizing single-point inertial measurement units: a systematic review. mHealth 2022;8:9.

Table S1 Summary of results and limitations of validation studies

Reference Trunk	Sensor(s)/Placement	Aim	Primary Measures and Analysis Methods	Conclusions	Limitations
Zijlstra & Hof, 2003	Tri-axial accelerometer attached over S2.	To validate a proposed algorithm and single-point accelerometer for spatio-temporal gait analysis against a treadmill with force transducers.	Heel strike (HS), stride duration, step length (SL), gait velocity (GV). Methods from Zijlstra, 2003.	GEs and temporal parameters can be obtained from lower trunk accelerations. Reasonable approximations of SL and GV can be obtained by application of an inverted pendulum model and generic correction factor.	Straight-walking in a laboratory limits external validity to daily-living. Healthy subjects limits applicability to pathological cohorts. Spatial parameter calculation required input of individual leg-length and is consistently underestimated before application of a 1.25 correction factor. 100% of GE were detected in only 9 subjects of a small sample size (n=15), 12% of foot contacts identified falsely in the other 6.
Henrikson <i>et al.,</i> 2004	Triaxial accelerometer at L3	To determine the test-retest reliability of trunk accelerometric gait analysis in healthy subjects based on autocorrelation methods.	Stride length, SL and cadence. Methods from Moe-Nilssen, 2004. RMS.	Trunk accelerometric gait analysis using autocorrelation methods in healthy adults is a reliable method.	Limited parameters. Straight-walking in a laboratory limits external validity to daily-living. Small sample size (n=20) of healthy subjects limits applicability to pathological cohorts. Limited parameters.
Brandes <i>et al.</i> , 2006	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer. Fitted on lower lumbar spine close to sacrum.	To determine if spatio-temporal parameters can be determined from lower trunk acceleration compared against video footage in healthy children.	Step count, traversed distance, walking time, GV, step duration and SL. Methods from Zijlstra, 2003.	Spatio-temporal gait parameters in children were accurately determined using trunk accelerometry. Inverted pendulum model and individual correction factor provides the possibility to estimate spatial gait parameters in children.	Straight-walking in a laboratory limits external validity to daily-living. Difficulty in children following protocol instructions could impact results. Small sample size (n=20). Healthy child cohort limits applicability to pathological child cohorts. Limited parameters.
Houdijk <i>et al</i> ., 2008	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer. Over posterior sacrum at body's centre of mass.	To evaluate the validity of the DynaPort for the assessment of spatiotemporal parameters of amputee gait against video footage.	Step count, SL, step duration and GV. Methods from Zijlstra, 2003.	DynaPort is a valid tool for determining mean spatiotemporal parameters in prosthetic gait. Although, errors between prosthetic and intact HS detection prevent reliable analysis of symmetry.	Straight-walking in a laboratory limits external validity to daily-living. Despite positive results for mean spatiotemporal parameters, poor assessment of mean step times of intact and prosthetic legs limits analysis of symmetry. Despite good agreement between both methods group means, large differences occur on individual level. Limited parameters.
Hartmann <i>et al.</i> , 2009	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed over S2	To determine the validity of DynaPort against an instrumented walkway for spatio-temporal gait parameters in older adults and to compare the levels of agreement for averaged step data from different walking distances and individual step data	GV, cadence, step duration and SL, SL variability, step duration and variability. Methods from Zijlstra, 2003.	DynaPort is a valid tool for spatio-temporal gait parameters for averaged step data in elderly at varying speeds. Gait variability measures and individual step data need to be viewed with caution.	Straight-walking in a laboratory limits external validity to daily-living. Small sample size (n=23). Instrumented walkway was not a gold standard for validating the IMU system with respect to gait variability and asymmetry.
Hartmann <i>et al.</i> , 2009. Esser <i>et al.</i> , 2011	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed over S2 IMU (MTx, Xsens, The Netherlands) containing a Tri-	To determine the reliability of spatio-temporal gait parameter measurement in older adults on different surfaces To determine correction factor required for PD, muscular	GV, cadence, step duration, SL, SL variability, step duration variability Methods from Zijlstra, 2003. Step time, SL and GV.	GV, cadence, step duration and step length under more challenging conditions can be reliably measured in independent living older adults. Gait variability measures need to be viewed with caution. Individual correction factors should be determined for patients suffering	Small sample size (n=23). Straight-walking in a laboratory limits external validity to daily-living.
Bautmans <i>et al.</i> , 2011	axial accelerometer, gyroscope and magnetometer attached over L4. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer	dystrophy, MND, stroke survivors and healthy subjects to estimate step and stride length. To investigate reliability of accelerometer gait analysis and correlation with clinical status and fall-risk.	Methods from Zijlstra, 2003. GV, step time asymmetry, methods from {Zijlstra, 2003 #37}.	from a neurological condition. 3D-accelerometry based gait speed and regularity showed high reliability when based on two walks of 18 m.	Stopwatch and observation employed as a reference platform. Limited parameters. Straight-walking in a laboratory limits external validity to daily-living.
Bugane <i>et al.</i> , 2012	placed over posterior sacrum. F4A (3-axis accelerometer, 3-axis gyroscope and 3-axis magnetometer. Fitted over L4–L5	To determine the validity of a single trunk accelerometer against stereophotogrammetry and dynamometry for measurement of spatio-temporal parameters in healthy subjects.	Step regularity., methods from Moe-Nilssen, 2004. SL, stride length, stride duration, step duration, stance duration, swing duration, double support duration, single support duration, GV and cadence. Methods from Zijlstra, 2003.	No statistically significant differences between IMU measurements and standard for most spatio-temporal parameters. Significant differences were found for gait cycle phases.	Subject must stand still for a few seconds before starting and for a few seconds after stopping which may impact results. Straight-walking in a laboratory limits external validity to daily-living. Healthy subjects limits applicability to pathological cohorts.
De Bruin <i>et al.</i> , 2012	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed over S2	To investigate the reliability of DynaPort in diabetic patients under single and dual task conditions on a challenging walking course	SL, GV, step duration, cadence Methods from Zijlstra, 2003.	Spatio-temporal parameters can be reliably measured in adults with diabetes using DynaPort under challenging surfaces.	Limited parameters.
Esser <i>et al.</i> , 2012	IMU (Tri-axial accelerometer, gyroscope and magnetometer) placed over L4.	Compare the trunk accelerations in PD subjects measured by an IMU with optical motion capture before deriving spatio-temporal gait measures.	Stride length, GV, step duration. Methods from Zijlstra, 2003.	No difference for trunk accelerations between IMU and OMCS data. No difference found for spatio-temporal parameters.	Small sample-size (n=10). Only recruited patients that could walk independently which may limit applicability to PD patients with increased disability. Limited parameters.
McCamley <i>et al.</i> , 2012	IMU (Freesense, Sensorize, srl) containing three accelerometers and three gyroscopes fitted over lumbar spine.	To propose improved methods for determining HS and TO and to assess accuracy of existing algorithms against instrumented mat.	HS, TO and stride duration. Methods from McCamley, 2012.	Newly proposed methods led to improved estimates of GE timing and improved estimate of individual step lengths.	Small sample (n=18) of healthy young adults limits applicability to pathological cohorts. Limited parameters.
Dalton <i>et al.</i> , 2013	AD_BRC sensor (triaxial accelerometer) attached to upper sternum.	To investigate the validity of a triaxial accelerometer in detecting gait and balance impairments in pre-manifest and manifest Huntington's disease (HD) subjects compared against a computerized walkway.	SL, stride length, cadence, step time, GV, Step time/SL/stride length variability, methods from Zijlstra, 2003. Step time asymmetry, step/stride regularity calculated. Methods from Moe-Nilssen, 2004.	Sensor showed excellent agreement to a computerized walkway across a range of spatio-temporal parameters and demonstrated significant discriminatory power between healthy, pre-manifest HD and manifest HD subjects.	Accelerometry patterns at level of the thorax are an attenuated version of those closer to the COM which could be a limitation. Instrumented walkway was not a gold standard for validating the IMU system with respect to gait variability.
Zijlstra <i>et al.</i> , 2013	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed over L2-4.	To compare reliability and validity of four different Inverted Pendulum estimations of step length in elderly subjects.	SL.	Evidence for reliable estimations of mean step length with good to high agreement to reference. No meaningful differences in results between models. Individual correction factors favoured over generic correction.	Limited parameters.
Godfrey <i>et al.</i> , 2014	Axivity AX3 sensor (Axivity, York, UK) located over L5.	To determine validity against an instrumented walkway and reliability of a single-point IMU and associated algorithms to assess gait in older and younger healthy adults at different speeds.	Step duration, stride duration, GV estimated, methods from McCamley, 2012. SL, methods from Zijlstra, 2003.	Sensor and algorithm arrangement are valid and reliable for quantifying gait in both younger and older adults.	Healthy cohort limit applicability to pathological cohorts.
Collett <i>et al.</i> , 2014	IMU device (Pi-node, Philips, Netherlands) containing a tri-axis accelerometer fitted over L4.	To determine test-retest reliability of spatio-temporal parameters and non-linear (phase plot) measures in HD patients and healthy controls.	GV, step time, step time variability, cadence, stride length, stride length variability, methods from Zijlstra, 2003. Non-linear measures (gait variability and symmetry).	There was no significant difference between any measure between tests.	Straight-walking in a laboratory limits external validity to daily-living. Only six cycles were used to calculate variability, which may have contributed to no difference being found in spatial temporal variability.
Trojaniello <i>et al</i> ., 2014	IMU (Opal <sup>™</sup> , APDM) featuring a 3-axis accelerometer and 3-axis gyroscope. Positioned at S2, L3, waist- level, L5 or right-side waist depending on algorithm employed.	To assess the performance of five methods McCamley, 2012; Zijlstra, 2003; Gonzalez, 2009; Kose, 2012 ; Shin, 2011 for detecting GEs and determining temporal parameters from a trunk/waist IMU compared to stereophotogrammetry and force platforms.	HS, TO, step time, stride time, swing time, double support time, stance time.	No statistically significant difference was found between all methods for stride and step duration and the standard. However, methods that detect TO in conjunction with HS that allow determination of stance, swing and double support time, showed a statistically significant difference in these measures against a standard.	Used sensors of different mass to the original study design and a barefoot walking protocol which differs from those originally employed. Healthy cohort limit applicability to pathological cohorts.
Godfrey <i>et al.</i> , 2015	Axivity AX3 sensor (Axivity, York, UK) fixed over L5.	To validate gait parameters from an IMU in a large cohort of young and older adults against an instrumented walkway.	Step count, step time, stride time, GV determined by methods from McCamley, 2012. SL using an inverted pendulum model from Zijlstra, 2003. Gait variability/asymmetry of each spatio-temporal parameter.	Step count and mean spatio-temporal characteristics had excellent/ good agreement with laboratory references. There was poor agreement between methods for estimates of left/right step data, variability and asymmetry. Determined it was due to inherent differences between the systems rather than inability of the sensor to measure the gait characteristics.	Healthy cohort limit applicability to pathological cohorts. IMU and instrumented walkway different data conversion principles may impact results. Instrumented walkway was not a gold standard for validating the IMU system with respect to gait variability and asymmetry.
Grimpampi <i>et al.</i> , 2015 Park & Woo, 2015	IMU (FreeSense, Sensorize s.r.I Rome) positioned over lower lumbar spine. Tri-axial accelerometer (G-Walk, BTS Bioenginering S.p.A., Italy) attached over L5.	To assess the reliability of gait variability measures in healthy older subjects from lower trunk accelerations. To determine the relationship between an accelerometer and foot pressure sensors for measuring gait characteristics in healthy subjects.	Stride time variability, methods from Zijlstra, 2003. GV, step count, cadence, stride length, stride duration, swing time, stance time, single support time, double support time, stride velocity, methods from Zilletra 2003.	Gait variability analysis from lower trunk acceleration data is reliable in older individuals. Significant and high correlation between the two systems with respect to GV and cadence. Stride length from the accelerometer was significantly and highly correlated with stride length and stride velocity from the foot processor	Limited number of strides so assessment was based only on linear techniques. Healthy cohort limit applicability to pathological cohorts. Straight-walking in a laboratory limits external validity to daily-living.
Trojaniello <i>et al.</i> , 2015	IMU (Opal™, APDM) featuring a 3-axis accelerometer and 3-axis gyroscope. Positioned at S2, waist-level or L5 depending on algorithm.	To assess the performance of three methods McCamley, 2012; Zijlstra, 2003; Shin, 2011 for determining GEs and gait temporal parameters from a single IMU in elderly, post-stroke, PD and HD subjects against an instrumented walkway.	HS, TO, GV, stride time, step time, stance time, swing time.	A universal decrease in accuracy of GE detection and temporal parameters compared to healthy subjects. No statistically significant differences in temporal parameter measurement between IMU methods in any cohort; apart from PD subjects for which methods from Zijlstra, 2003 outperformed.	Limitations include using sensors of different mass to the original study design and a barefoot walking protocol which differs from those originally employed. Limited parameters.
Byun <i>et al</i> ., 2016	FITMETER <sup>®</sup> (FitLifeInc, Suwon, Korea, hereafter FITMETER) containing a tri-axial accelerometer over L5.	To investigate the validity and test-retest reliability of spatio- temporal gait parameters measured with a single tri-axial accelerometer compared to an instrumented walkway.	Cadence, GV, step time, step time variability and asymmetry, methods from McCamley, 2012. SL, methods from Zijlstra, 2013.	Gait parameters from a single accelerometer were reliable and valid with advantages over the walkway system for measuring gait variability and asymmetry.	Length of the active instrumented walkway was too short to capture enough consecutive steps to allow reliable variability measures. Inclination of the accelerometer was not considered. Instrumented walkway was not a gold standard for validating the IMU system with respect to gait variability and asymmetry.
Hickey <i>et al.</i> , 2016	Axivity AX3 sensor (Axivity, York, UK) located on L5.	To examine the validity of a single wearable for deriving spatio-temporal gait characteristics in spinocerebellar ataxia type-6 and control cohorts against an instrumented walkway.	GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, swing time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry, methods	Mean gait characteristics can be accurately measured using an accelerometer-based wearable in people with SCA6. Although, gait variability and asymmetry showed poor agreement between the two systems.	Instrumented walkway was not a gold standard for validating the IMU system with respect to gait variability and asymmetry. IMU and instrumented walkway different data conversion principles may impact results. Straight-walking in a laboratory limits external validity to daily-living.
Sejdic <i>et al.</i> , 2016	Tri-axial accelerometer (MMA7260Q, Freescale Semiconductor) secured over the L3.	To validate a proposed algorithm against a motion capture system for healthy elderly, PD and peripheral neuropathy subjects.	from McCamley, 2012. Stride time, HS, TO, stance time, double support duration, single support duration, swing percentage and HB.	Demonstrated the proposed algorithm can accurately extract heel and toe events from gait accelerometry signals.	Treadmill protocol limits validity to overground walking and daily-life scenarios. Treadmill acted as an external pacer which greatly aided the gait of PD subjects which could alter results.
Storm <i>et al.</i> , 2016	IMUs (Opal <sup>™</sup> , APDM) containing a 3-axis accelerometer, 3-axis gyroscope, and a 3-axis magnetometer. Positioned on L5. The other two IMUs	To evaluate the accuracy of two algorithms versus pressure insoles for the detection of gait events and temporal parameters based on two shank-worn inertial sensors, and the other based on one waist-worn sensor	HS, TO, stride time, step time and stance time, methods from McCamley, 2012.	Despite the multi-sensor shank method performing better, both methods showed small differences in GE timing and temporal parameter estimation, for both mean and variability measures, between different environments and different walking protocols	Small sample size (n=10) of healthy subjects limits applicability to pathological cohorts. Limited parameters.
Lim & Lee, 2017	Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy).	To determine the correlation between accelerometer and treadmill-based analysis of gait parameters during comfortable walking in healthy young adults.	Cadence, GV, step count, step time, stride time, stance phase time, swing phase time and double support time, methods from Zijlstra, 2003.	Measures from the accelerometer strongly correlated with those from the treadmill-based system.	Small sample size (n=23) of healthy adults was a limitation and limits applicability to pathological cohorts. Treadmill-based walking limits external validity to daily-living scenarios.
Oyake <i>et al.</i> , 2017	Tri-axial accelerometer (WAA-006; Wireless Technologies Inc., Japan) at L3.	To evaluate the validity of step time and length asymmetries using an accelerometer against force plate measurements in hemiparetic stroke subjects.	GV, step time asymmetry and SL asymmetry.	Step time asymmetry and SL asymmetry estimated from trunk accelerations significantly correlated to that measured using force plates.	Small sample size (n=24). Straight-walking in a laboratory limits external validity to daily-living. Limited parameters.
Storm <i>et al.</i> , 2018	Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, just above the malleoli.	To characterise gait in both laboratory and daily life conditions for patients with MS. Algorithms to characterise gait from wearable inertial sensors data were also validated.	HS, TO, stride time, step time, stance time, swing time, stride time variability, step time variability, stance time variability, swing time variability, step count and GV, methods from McCamley, 2012.	Validated trunk accelerometry methods to quantify gait in MS subjects and showed how gait characteristics.	Variability measures were highly overestimated. Small sample size (n=14).
Zago <i>et al.</i> , 2018	Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.	To determine if a commercial IMU can reliably provide the main spatiotemporal gait parameters in PD subjects compared to optical motion capture standard.	Cadence, GV, stride length, stride duration, step duration, stance phase duration, swing phase duration and double support phase duration, methods from Zijlstra, 2003.	Most spatio-temporal gait parameters detected by the IMU were not statistically different. GV was significantly higher when measured with the wearable system. Stride length and step duration and double support duration, although not statistically different, showed moderate RMS and mean absolute errors.	Difference detected in some parameters was probably due to the different algorithm used in the two devices to detect gait events. Small sample size (n=22). Straight-walking in a laboratory limits external validity to daily-living.
De Ridder <i>et al.</i> , 2019	Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.	To confirm the test-retest reliability and concurrent validity of a commercially available accelerometer for spatio-temporal gait parameters with an instrumented walkway standard.	GV, cadence, stride length, stride duration, stance duration, swing duration, double support, and single support, methods from Zijlstra, 2003.	Accelerometer is reliable for all measured spatio-temporal parameters. Excellent validity shown for GV, cadence, stride length and stride duration. Cautious interpretation necessary for temporal parameters based on final foot contact (stance, swing and single/double support time).	Measured spatio-temporal parameters at a single speed might have an impact on accuracy. Straight-walking on a treadmill limits external validity to daily-living. Healthy cohort limit applicability to pathological cohorts.
Waist Kose <i>et al.,</i> 2012	IMU (FreeSense, Sensorize <sup>®</sup> ) containing a tri-axial accelerometer and two bi-axial gyroscopes attached to right-side of waist.	To validate a proposed method for SL estimation on healthy subjects at various speeds against stereophotogrammetry.	HS, step duration, SL and distance travelled.	Step length was estimated for all subjects with less than 3% error. Traversed distance was assessed with less than 2% error.	Accuracy discrepancies between left and right steps, hypothesised to be due to asymmetrical sensor placement and fixation to the subject's belt rather than skin. Small sample size (n=9). Limited parameters. Healthy cohort limit applicability to pathological cohorts.
Ear Atallah <i>et al.</i> , 2014	e-AR sensor. (containing a tri-axial MEMS accelerometer) fitted behind the ear.	To validate an ear-worn accelerometer against a force- plate treadmill for detection of stride duration and step time asymmetry in older adults and orthopaedic patients.	Stride duration and step time asymmetry.	Ear-worn accelerometer was capable of determining gait cycle time, and step-period asymmetry with good correspondence to a force-plate treadmill regardless of inclines or speed.	Fixed speeds and inclines on a treadmill could lead to less asymmetry and gait cycle time variability and alter validity. Did not analyse individual variability only group means based on condition. Straight-walking on a treadmill limits external validity to daily-living. Limited parameters.
Jarchi <i>et al.</i> , 2014	e-AR sensor. (containing a tri-axial MEMS accelerometer) fitted behind the ear.	To determine quantitative accuracy of the e-AR sensor for detection of GEs against an in-shoe pressure detection system.	HS and TO.	The e-AR sensor is valid for the detection of GEs in straight walking conditions. With higher accuracy for HS than TO.	Straight-walking protocol limits external validity to daily-living. Healthy cohort limit applicability to pathological cohorts. Small sample size (n =10). Limited parameters.
Jarchi <i>et al.</i> , 2015	e-AR sensor. (containing a tri-axial MEMS accelerometer) fitted behind the ear.	Determine detection of GEs in PD patients from an e-AR sensor compared to motion capture.	HS, TO and step frequency.	Good agreement between e-AR sensor and motion capture for detection of GEs and step frequency.	Straight-walking protocol limits external validity to daily-living. Small sample size (n =9). Limited parameters.
Jarchi <i>et al.</i> , 2016	e-AR sensor. (containing a tri-axial MEMS accelerometer) fitted behind the ear.	Determine detection of GEs in orthopedic patients from an e-AR sensor compared to an in-shoe pressure detection system.	HS and gait asymmetry.	Good agreement between e-AR sensor and in-shoe pressure system for detection of GEs and step frequency.	Straight-walking protocol limits external validity to daily-living. Small sample size (n =8). Limited parameters.
Snank Li <i>et al.</i> , 2010	IMU (bi-axial accelerometer and a gyroscope) attached to the lateral aspect of the calf.	To study the feasibility of estimating GV using a shank mounted IMU versus treadmill.	GV.	Speed estimation method worked well across treadmill speeds and slopes. It also worked well during overground walking. Accuracy is comparable to that achieved from foot-mounted sensors.	Healthy cohort limit applicability to pathological cohorts. Straight-walking on a treadmill limits external validity to daily-living. Small sample size (n =8). Inability to assess asymmetry.
Maqbool <i>et al.</i> , 2017	IMU consisting of a tri-axis accelerometer and a tri- axis gyroscope over the shank. Gyroscope signal is the only used.	To validate a shank IMU against pressure insoles for gait event detection in lower limb amputees when performing level ground and ramp activities.	HS and TO.	IC and TO events accurately detected using the proposed system in control subjects and amputees when performing activities of daily living.	Small cohort of two amputees. Protocol of only straight-walking. Need for the instrumented shank to take the first step to allow first TO detection. Inability to assess asymmetry. Limited parameters.
Foot Sabatini <i>et al.,</i> 2005	IMU (one biaxial accelerometer and one gyroscope) attached to superior aspect of a single shoe.	To determine accuracy of the foot inertial sensing approach in assessing walking speed and the incline on a treadmill.	HS, TO and GV.	Foot inertial sensing is a promising tool for the reliable identification of subsequent gait cycles and the accurate assessment of walking speed and incline.	Difficult attachment of the IMU to the shoe and an accuracy decrease with increasing incline further limit clinical application. Healthy cohort limit applicability to pathological cohorts. Straight-walking on a treadmill limits external validity to daily-living. Small sample size (n =5). Inability to assess asymmetry.
Song & Kim, 2018	IMU (tri-axis accelerometer, gyroscope) attached to the rear of a single shoe.	To propose a foot IMU and algorithm aimed to classify gait activities and to determine accuracy of gait parameters when compared to motion capture.	Stride length, stride time, GV and step count.	Proposed system is simple and effective for daily-life gait analysis, including gait activity classification and gait parameter estimation for each activity.	Limited parameters. Difficulties were present with detecting tip-toed stair walking with lack of evident HS. Inability to assess asymmetry. Limited parameters.
Smart Device LeMoyne <i>et al.</i> , 2010	iPhone 3G attached above lateral malleolus of left ankle.	To establish the capacity of an iPhone accelerometer to accurately acquire gait parameters.	Time averaged acceleration and step cycle time.	The iPhone accelerometer has the capacity to accurately quantify gait parameters accurately.	Unrealistic attachment of the device above the lateral malleolus does not accurately reflect phone placement in everyday life, limiting applicability Healthy cohort limit applicability to pathological cohorts. Straight-walking in laboratory conditions limits external validity to daily-living. Small sample size (n=1)
Pepa <i>et al.</i> , 2017	iPhone 4s placed at approximately L3-4 and lateral waist.	To assess smartphone performance in different locations in heel strike, step count, step period, and step length estimation compared to stereophotogrammetry.	Step count, HS, Step time and SL.	High correlations found between smartphone and stereophotogrammetry measures. Error ranges comparable to those in the literature. Smartphone placement did not affect the performance.	Limited parameters. Device orientation had an effect on step count sensitivity. SL estimation means need for calibration of individual correction factor. Phone positioning on lumbar spine and lateral waist does not accurately reflect phone placement in everyday life, limiting applicability. Healthy cohort limit applicability to pathological cohorts. Straight-walking in laboratory conditions limits external validity to daily-living. Small sample size (n=11). Limited parameters.
Silsupadol <i>et al.</i> , 2017	Vivo X5 one of five locations: 1) Over L3; 2) in a shoulder bag on the right hip; 3) above the front right pant pocket horizontal orientation; 4) in the right hand, held in a telephone speaking position; 5) in the front right pant pocket placed in a vertical orientation.	To assess the reliability and validity of a smartphone- based accelerometer in quantifying spatio-temporal gait parameters when attached to the body or in a bag, belt, hand, and pocket compared with instrumented walkway.	SL, GV, step time and cadence.	Smartphone-based assessments of gait are reliable and valid when placed on the body, bag, or belt, particularly in comfortable and fast walking conditions.	Limitations in assessing gait at slow speeds reduces application to pathological groups. Straight-walking with only 5-9 steps per trial in laboratory conditions limits external validity to daily-living. Healthy cohort limit applicability to pathological cohorts. Limited parameters.

Table S2 Summary of clinical application studies

		Application	Falameters measured
Trunk			
Auvinet <i>et al.</i> , 2003	Locometrix (tri-axial accelerometer) over L3-4.	Gait abnormalities in elderly fallers versus healthy controls.	GV and stride frequency, length, symmetry and regularity.
Moe-Nilssen et al. 2003	Triaxial niezoresistant accelerometer (Logger Technologi, Malmö, Sweden) over lower back	Discriminate between children with dyclevia and bealthy controls based on gait	GV cadence and SI
Houdijk <i>et al.</i> , 2008	DynaPort MiniMod (MicRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer.	Assessment of spatiotemporal parameters of amputee galt.	Step count, SL, step duration and GV.
Minuika at al. 2000		Describe asit of strake nations, delinests from bealthy controls	CV SL stride duration codence stride regularity and DMC
	In-axial accelerometer (RF-H46C, Hitachi Metals, Ltd., Japan) over L3.	Describe gait of stroke patients delineate from healthy controls.	GV, SL, Stride duration, cadence, stride regularity and RMS.
Maquet <i>et al.</i> , 2010	Locometrix (tri-axial accelerometer) over L3-4.	Delineation of elderly, Alzheimer's and mild cognitive impairment subjects by gait analysis under single	GV, stride frequency, stride length, stride symmetry and stride regularity.
Lamoth <i>et al.</i> , 2010	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer	Differentiate transfemoral amputees and healthy controls based on gait.	GV, stride time, stride time variability, non-linear measures (variability, regularity, stability) and RMS.
	over L3.		
Bautmans <i>et al.</i> , 2011	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer	Delineating healthy elderly and young subjects from elderly fallers from gait.	GV, step time, step time symmetry, step regularity and stride regularity.
	placed over S2.		
Esser <i>et al.</i> , 2011	IMU (MTx, Xsens, The Netherlands) containing a Tri-axial accelerometer, gyroscope and magnetometer,	PD, muscular dystrophy, MND, stroke survivors and healthy subjects.	Step time, SL and GV.
Lamoth et al., 2011	over L3.	Elect of dual task conditions on gait in Dementia subjects and healthy controls.	stability).
Meijeretal 2011	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triavial accelerometer	Gait in nost-stroke patients versus healthy controls	GV cadence, gait symmetry and bilateral coordination of gait
	Over posterior sacrum at body's centre of mass.		av, cadence, gait symmetry and bilateral coordination of gait.
Bolink et al., 2012	MicroStrain® Inertia-Link® was used containing gvroscopes and accelerometers. Attached over dorsal	Objective assessment of total knee replacement in osteoarthritis patients and differentiating from healthy	GV. cadence. SL. step time, step time variability and step time asymmetry.
,,	side of the pelvis between both posterior superior iliac spines.	controls.	
De Bruin <i>et al.</i> , 2012	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer	Determining severity of peripheral neuropathy in diabetics.	SL, GV, step duration and cadence.
	placed over S2.		
Hojan <i>et al.</i> , 2014	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer.	External breast prosthesis effect on gait after mastectomy.	GV, SL, step time, cadence and step time asymmetry.
	Over posterior sacrum at body's centre of mass.		
Dalton et al., 2013	AD_BRC sensor (triaxial accelerometer) attached to upper sternum.	Differentiating between pre-manifest HD, manifest HD and healthy controls.	SL, stride length, cadence, step time, GV, Step time/SL/stride length variability, step asymmetry and step/
			stride regularity.
Doi <i>et al.</i> , 2013	Tri-axial accelerometer (MVP-RF8, MicroStone, Nagano, Japan) attached to L3.	Effect of multicomponent exercise on gait in elderly with MCI.	GV, stride time, stride length and HR.
Esser <i>et al.</i> , 2013	IMU (Pi-Node, Philips, Netherlands) over L4.	Differentiate PD patients and healthy controls.	Cadence, stride length, GV, cadence variability, stride length variability and non-linear measures (gait
			variability).
losa <i>et al.</i> , 2013	FreeSense (Sensorize s.r.l., Rome, Italy) containing a tri-axial accelerometer at L2-3.	Differentiating Cerebral Palsy children from healthy controls during running and walking.	GV, SL, step duration, RMS and HR.
Manikowska <i>et al.</i> , 2013	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer.	Gait patterns in pre and post-menopausal women.	GV, SL, cadence, stance phase duration, swing phase duration, single support duration, double support
	Over posterior sacrum at body's centre of mass.		duration and SL variability.
Manikowska <i>et al.</i> , 2013	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer.	Effect of hippotherapy on gait in cerebral palsy children.	GV, cadence, SL, stride length and left-right symmetry.
	Over posterior sacrum at body's centre of mass.		
Collett <i>et al.</i> , 2014	IMU device (Pi-node, Philips, Netherlands) containing a tri-axis accelerometer fitted over L4.	Delineating HD patients from healthy controls and determining disease severity using gait.	GV, step time, step time variability, cadence, stride length, stride length variability and non-linear measures
			(gait variability and symmetry).
Herman <i>et al.</i> , 2014	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer	Quantify motor differences in PD subtypes and propose a classification scheme.	Step count, GV, stride time variability, stride regularity and cadence.
	fixed over the lower back.		
Pau <i>et al.</i> , 2014	Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-L5.	Effect of physical activity on balance and gait of older adults.	SL, GV, gait cycle duration, stance duration, swing duration and double support duration.
Saether <i>et al.</i> , 2014	(MTx. XSens, Enschede, NL) attached over L3 contains tri-axial units of accelerometers, gyroscopes, and	Gait characteristics in cerebral palsy versus healthy children.	GV, cadence, SL, step time, stride regularity and symmetry.
	magnetometers.		
Arvin <i>et al.</i> , 2015	DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer	Effect of unilateral hip abductor muscle fatigue on gait in older adults.	Stride time, stride time variability, step symmetry, stance time, HR and non-linear measures (gait stability).
	placed over L5.		
Demonceau <i>et al.</i> , 2015	Locometrix (tri-axial accelerometer) over L3-4.	Delineating PD patients from healthy controls and determining disease severity.	Cadence, SL, gait regularity and symmetry.
Martinez-Ramirez et al., 2015	IMU (MTx, Xsens, The Netherlands) containing a Tri-axial accelerometer, gyroscope and magnetometer	Frailty assessment based on gait assessment.	GV, cadence, step regularity, stride regularity, gait symmetry, step time, step time variability, RMS and HR.
	over the lumbar spine.		
Matsushima <i>et al.</i> , 2015	Triaxial accelerometer (Jukudai Mate; Kissei Comtec Co., Ltd., Matsumoto, Japan) fixed over L3.	Delineating Ataxia patients from healthy controls and determining disease duration.	GV, cadence, SL, gait regularity and RMS.
Perrochon <i>et al.</i> , 2015	Locometrix (tri-axial accelerometer) over L3-4.	Effects of exercise on gait in dementia patients.	GV, stride frequency, stride length, gait symmetry and gait regularity.
Rapp <i>et al.</i> , 2015	IMU (Humotion, Münster, Germany) featuring a tri-axis accelerometer and tri-axis gyroscope attached	Efficacy of rehabilitation for patients after hip arthroplasty.	GV and gait symmetry.
	over L4-5.		
Terrier & Reynard, 2015	Tri-axial accelerometer (Physilog $^{\oplus}$ System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.	Effect of aging on gait parameters.	GV, non-linear measures (gait stability), RMS and walk-ratio.
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A.,	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls.	GV, non-linear measures (gait stability), RMS and walk-ratio. GV, SL, stride length and cadence.
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls.	GV, non-linear measures (gait stability), RMS and walk-ratio. GV, SL, stride length and cadence.
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls.	GV, non-linear measures (gait stability), RMS and walk-ratio. GV, SL, stride length and cadence. Stride time, step time, stride regularity, step regularity and gait symmetry.
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached pear COM</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability, and non-linear measures (gait</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Gillain <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Deleineating between PD patients and age-matched controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Gillain <i>et al.</i> , 2016 Hatanaka <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Deleineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Gillain <i>et al.</i> , 2016 Hatanaka <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Gillain <i>et al.</i> , 2016 Hatanaka <i>et al.</i> , 2016 Henderson <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Deleineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Gillain <i>et al.</i> , 2016 Hatanaka <i>et al.</i> , 2016 Henderson <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Gillain <i>et al.</i> , 2016 Hatanaka <i>et al.</i> , 2016 Henderson <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Deletermining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, stance time variability.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Hatanaka <i>et al.</i> , 2016 Henderson <i>et al.</i> , 2016 Hickey <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability.</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Gillain <i>et al.</i> , 2016 Hatanaka <i>et al.</i> , 2016 Henderson <i>et al.</i> , 2016 Hickey <i>et al.</i> , 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, step time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Gillain et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, stance time variability, stance time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Gillain et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, stance time variability, stance time variability, step time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, gait symmetry, step time variability, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Gillain et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A.,</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, stpe time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, swing time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Gillain et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Deleremining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, stpe time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, step time variability, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Gillain et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, stpe time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, swing time variability.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry,</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Pau et al., 2016 Van Schooten et al., 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, stpe time variability, stance time variability, step time, stance time, step time symmetry, swing time, stance time, step time symmetry, swing time symmetry, and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, non-linear measures (gait smoothness, complexity, intensity) and stride frequency.</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, stance time variability, step time variability, step time variability, step time variability, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, non-linear measures (gait smoothness, complexity, intensity) and stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, stance time variability, stance time variability, stance time variability, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, non-linear measures (gait smoothness, complexity, intensity) and stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, step time variability, step time asymmetry, step time</li> </ul>
Terrier & Reynard, 2015 Awotidebe <i>et al.</i> , 2016 Barden <i>et al.</i> , 2016 Clermont <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2016 Hatanaka <i>et al.</i> , 2016 Henderson <i>et al.</i> , 2016 Hickey <i>et al.</i> , 2016 Martinez-Ramirez <i>et al.</i> , 2016 Mutoh <i>et al.</i> , 2016 Pau <i>et al.</i> , 2016 Van Schooten <i>et al.</i> , 2016 Del Din <i>et al.</i> , 2017	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delermining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, stpe time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, stance time variability, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait southness, complexity, intensity) and stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, stance time variability, stance time asymmetry, SL asymmetry, step velocity, SL, swing time terquality, step time, swing time, stance time, step time asymmetry, swing time asymmetry, step time variability, its tep time variability, stance time asymmetry, SL asymmetry, step velocity, SL, swing time variability, step time variability, GV variability.</li> </ul>
Terrier & Reynard, 2015         Awotidebe et al., 2016         Barden et al., 2016         Clermont et al., 2016         Del Din et al., 2016         Gillain et al., 2016         Hatanaka et al., 2016         Henderson et al., 2016         Martinez-Ramirez et al., 2016         Mutoh et al., 2016         Van Schooten et al., 2016         Van Schooten et al., 2017         Pau et al., 2017	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Delemeating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, stance time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, stance time variability, stance time variability, step time, step time variability, stance time variability, step time, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, stance time, step time asymmetry, swing time asymmetry, gait variability, stance time asymmetry, step velocity, SL, swing time variability, step time variability, stance time asymmetry, SL asymmetry, step velocity, SL, swing time variability, step time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, stance, swing and double support phase duration.</li> </ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM. Tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM. Tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Triaxial accelerometer fixed to participant's sacrum. IMU (tri-axial accelerometer and gyroscope) fixed to the lower back.	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Deletermining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait in early MS subjects compared to healthy control. Gait in early MS subjects compared to healthy control.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, stpe time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, SL variability, stance time variability, stance time variability, stance time variability, stance time variability, swing time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, stride length, gait symmetry, gait variability, stride length, gait symmetry, gait variability, stance time asymmetry, step time asymmetry, step time asymmetry, swing time asymmetry, stance time asymmetry, stance time asymmetry, stance time asymmetry, stance time, step time asymmetry, stance time asymmetry, stance time asymmetry, stance time asymmetry, stance time, step time variability, stance time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, stance, swing and double support phase duration.</li> &lt;</ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2018	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM. Tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axis gyroscope, tri-axis magnetometer fixed over L3. ITri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached oruc L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L4-5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer fixed to participant's sacrum. IMU (tri-axial accelerometer and gyroscope) fixed to the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait characteristics as a predictor of falls in older subjects. Gait characteristics as a predictor of falls in older subjects. Gait in early MS subjects compared to healthy control. Gait in early MS subjects compared to healthy control. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, sung time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, sung time variability, step time, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait symmetry, step time variability, stride length, gait symmetry, gait variability, stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, stride length, GV, stride time variability, GV variability, step lene, step time asymmetry, stance time asymmetry, step time, step time, step time, swing time asymmetry, step time asymmetry, step time, step time, step time, step time, swing time variability, stride length, gait symmetry, step time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, stance, swing and double support phase duration.</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Esser et al., 2018 Pau et al., 2018	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer fixed to participant's sacrum.</li> <li>IMU (tri-axial accelerometer and gyroscope) fixed to the lower back.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer fixed to participant's sacrum.</li> <li>IMU (tri-axial accelerometer and gyroscope) fixed to the lower back.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned</li> </ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, stpe time variability, stance time variability, step time, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, step time variability, stance time variability, stance time variability, step time, swing time, stance time, step time variability, stance time variability, stance time variability, step time, swing time, stance time, step time variability, stance time variability, step time, swing time symmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, non-linear measures (gait smoothness, complexity, intensity) and stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, stance time asymmetry, step velocity, SL, swing time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, stance, swing and double s</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Esser et al., 2018 Pau et al., 2018 Storm et al., 2018	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM. Tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, just above the malleoli.	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait in early MS subjects compared to healthy control. Gait in early MS subjects compared to healthy control. Effect of texting while walking on gait in MS patients compared to healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride time variability, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, stance time variability, swing time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, stance time asymmetry, step velocity, SL, swing time asymmetry, swing time asymmetry, step velocity, SL, swing time variability, step time variability, step time variability, GV variability.</li> <li>Cadence, speed, stride length, step time, swing duration and double support duration.</li> <li>Step time, cadence, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Step time, cadence, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support d</li></ul>
Terrier & Reynard, 2015         Awotidebe et al., 2016         Barden et al., 2016         Clermont et al., 2016         Del Din et al., 2016         Gillain et al., 2016         Hatanaka et al., 2016         Henderson et al., 2016         Martinez-Ramirez et al., 2016         Mutoh et al., 2016         Van Schooten et al., 2016         Del Din et al., 2017         Pau et al., 2017         Pau et al., 2018         Pau et al., 2018         Storm et al., 2018         Tanigawa et al., 2018	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridgeshire, UK) attached near COM. Tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer and gyroscope) fixed to the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, just above the malleoli. MVP-RF-8, MicroStone Co., Nagano, Japan) that contained a triaxial angular rate gyroscope and a	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride time variability, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, swing time variability.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, stance time variability, stance time variability, swing time asymmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, step time variability, stride length, gait symmetry, gait variability, step time variability.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, step time, swing time, stance time, step time asymmetry, swing time asymmetry, stance time variability.</li> <li>Cadence, speed, stride length, step time, swing time, stance time, step time variability, step time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance time, swing time, stride time variability, step time</li></ul>
Terrier & Reynard, 2015         Awotidebe et al., 2016         Barden et al., 2016         Clermont et al., 2016         Del Din et al., 2016         Gillain et al., 2016         Hatanaka et al., 2016         Henderson et al., 2016         Martinez-Ramirez et al., 2016         Mutoh et al., 2016         Van Schooten et al., 2016         Del Din et al., 2017         Pau et al., 2017         Pau et al., 2018         Pau et al., 2018         Tanigawa et al., 2018	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerfand) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM. Tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer fixed to participant's sacrum. IMU (tri-axial accelerometer fixed to participant's sacrum. IMU (tri-axial accelerometer fixed NFS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of taxing while walking on gait in MS patients compared to healthy controls. Effect of taxing while walking on gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, stance time, step time variability, stance time variability, stance time variability, step time asymmetry, step time symmetry, stance time asymmetry.</li> <li>GV, SL, swing time variability, step time, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, suing time asymmetry, step velocity, SL, swing time asymmetry, SL variability, stride length, GV, stance time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, stride length, GV, stride time variability, GV variability, stride length rom-linear measures (gait smoothness, complexity, intensity) and stride frequency.</li> <li>Step count, mean bout length, stap time, swing time, stance time, step time variability, step time variability, step time variability.</li> <li>Cadence, speed, stride length, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Hs ro, stride line, step time, stance time, swing time, stride time</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2018 Pau et al., 2018 Storm et al., 2018 Storm et al., 2018	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (Int-axis gyroscope, tri-axis magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Acivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer fixed to participant's sacrum.</li> <li>IMU (tri-axial accelerometer and gyroscope) fixed to the lower back.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, just above the malleoli.</li> <li>MVP-RF-</li></ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls. Effect of texting while walking on gait in pregnant patients.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability, and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, swing time variability.</li> <li>GV, SL, swing time variability.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability.</li> <li>GV, SL, swing time variability, step time, step time asymmetry, stance time, step time variability, stance time variability, swing time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, non-linear measures (gait smoothness, complexity, intensity) and stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time variability, stance time variability. GV and SL variability.</li> <li>Cadence, speed, stride length, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Step time, cadence, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Ho, O, stride line, step time, stence time, swing t</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Matoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2017 Esser et al., 2018 Pau et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Waist Terrier et al., 2009	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM. Tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Acivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer fixed to participant's sacrum. IMU (tri-axial accelerometer and gyroscope) fixed to the lower back. Tri-axial accelerometer fixed to participant's sacrum. IMU (tri-axial accelerometer G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, just above the malleoli. MVP-RF-8, MicroStone Co., Nagano, Japan) that contained a triaxial angular rate gyroscope and a linear accelerometer were attached to a fixed belt at the level of the L3.	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls. Effect of texting while walking on gait in pregnant patients. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, stpe time variability, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, stance time variability, step time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, step time, stance time, step time asymmetry, say and stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, step velocity, SL, swing time variability, step time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>HS, TO, stride time, step time, swing time, stride time variability, step time va</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Matoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Esser et al., 2017 Esser et al., 2018 Pau et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Waist Terrier et al., 2009 Yang et al., 2011	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Galtup, Lausanne, Switzerland) Scm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (MC-Boberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (MC-Boberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer and gyroscope) fixed to the lower back.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two</li></ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait nearly MS subjects compared to healthy control. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of exiting while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures. Differentiating PD and healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time, step time variability, and clouble support time.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, swing time asymmetry, stap time asymmetry, stance time variability, sure asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, cadence, stance duration, swing ture, stance time, step time asymmetry, staine time variability, step time asymmetry, stance time asymmetry, stance time variability, SL variability.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, cadence, stance duration, swing time, stance time, step time asymmetry, stance time variability, step time variability.</li> <li>Cadence, speed, stride length, stance, swing and double support phase duration.</li> <li>Step time, cadence, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance time, swing time, stride time variability, step time</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Handerson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2018 Storm et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Waist Terrier et al., 2009 Yang et al., 2011	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Galtup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTX (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (tri-axis gyroscope, tri-axis magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Malk, BTS Bioengineering S,p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (MoMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back.</li> <li>Tri-axial accelerometer (MoVentin, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back.</li> <li>Tri-axial accelerometer (MoVentin, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back.</li> <li>Tri-axial accelerometer (Movennitor, Version 2.8.1, Mc Robert</li></ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures. Differentiating PD and healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability. GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time variability.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, stance time variability, stance time variability, swing time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, GV variability, SL variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, tride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, Stride length, variability, stride length, GV, stride time, stance time, stance time, stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>HS, TO, stride time, stance time, swing time, stride time variability, step time variability, stance time variability, step count, GV</li> <li>Gait symmetry and stride variability.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>HS, TO, stride line, step time, stance time, swi</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Hatenderson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2017 Esser et al., 2018 Pau et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Waist Terrier et al., 2009 Yang et al., 2011 Terrier et al., 2017	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Galtup, Lausanne, Switzerland) Scm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer (growther, gyroscope and magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axis al accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, just above the malleoii.</li> <li>MVP-RF-8, MicroStone Co., Nagano, Japan) that contained a triaxial accelerometer.</li> <li>Physilog system (BioAGM, Switzerland), triaxial accelerometer lateral waist.</li> <li>Tri-axial accelerometer at lateral waist.</li> <li>Tri-axial acceleromet</li></ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Differentiating PD and healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, SL variability, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, stance time asymmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, gait variability, stance time asymmetry, stance time asymmetry, stance time asymmetry, stance time asymmetry, stance time variability, step time variability, stance time variability, SL variability.</li> <li>Cadence, speed, stride length, stance, swing and double support phase duration.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, cadence, stance time, swing time, stance time, step time variability, stance time variability, step count, GV</li> <li>Cadence, speed, stride length, stance, swing and double support phase duration.</li> <li>Str</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Handerson et al., 2016 Hickey et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2017 Pau et al., 2018 Pau et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Waist Tanigawa et al., 2018 Waist Terrier et al., 2009 Yang et al., 2011 Terrier et al., 2017 Foot	<ul> <li>Tri-axial accelerometer (Physilog<sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Tri-axial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mirnamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Ital</li></ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures. Differentiating PD and healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, step time, step time asymmetry, stance time variability, and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, SL asymmetry, stance time symmetry, SL asymmetry, stance time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, Stance, swing and double support phase duration.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support variability, step time variability, stance time variability, stance time variability.</li> <li>Stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV cadence, stance time, swing time, stride time variability, step time variability, stance time variability, step count, GV</li></ul>
Terrier & Reynard, 2015Awotidebe et al., 2016Barden et al., 2016Clermont et al., 2016Del Din et al., 2016Hatanaka et al., 2016Henderson et al., 2016Martinez-Ramirez et al., 2016Mutoh et al., 2016Van Schooten et al., 2016Del Din et al., 2017Esser et al., 2018Pau et al., 2018Van g et al., 2018Yang et al., 2011Terrier et al., 2017FootChung et al., 2017	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridge, UK), attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM. Tri-axial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer fixed to participant's sacrum. IMU (tri-axial accelerometer fixed to participant's sacrum. IMU (tri-axial accelerometer G-Walk, BTS Bioengineering S, P.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S, P.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S, P.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S, P.A., Italy) Attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S, P.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioeng	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between RD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures. Differentiating PD and healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, and the cegularity, gait symmetry, step time variability, stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, step time, swing time, stance time, step time variability, step time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and non-linear measures (gait control variability, step time variability, stance time variability, GV and SL variability.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>HS, TO, stride time, step time, swing time, stride</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Handerson et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2017 Esser et al., 2018 Pau et al., 2018 Pau et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Waist Terrier et al., 2010 Yang et al., 2011 Terrier et al., 2017 Foot Chung et al., 2012 Angthong & Veljkovic, 2018	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Tri-axial accelerometer (GENEActiv, Cambridge, UK), attached over L3. tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axis gyroscope, tri-axis magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, just abve the malleoli. MVP-RF-8, MicroStone Co., Nagano, Japan) that contained a triaxial angular rate gyroscope and a linear accelerometer were attached to a fixed belt at the level of the L3. Physilog system (BioAGM, Switzerland), triaxial accelerometer lateral waist. Tri-axial accelerometer on superior aspect of right foot. Foot pod (Garmin Ltd., Kansas City, USA) strapped to dorsum of foot.	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait in early MS subjects compared to healthy control. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Differentiating PD and healthy controls. Delineating patients with chronic pain of lower limbs and healthy controls. Differentiating PD and healthy controls. Differentiating PD and healthy controls. Differentiating PD and healthy controls. Delineating patients with chronic pain of lower limbs and healthy controls. Delineating patients with chronic pain of lower limbs and healthy controls. Delineating patients with chronic pain of lower limbs a	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, cadence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, cadence, step time, step time, swing time, stance time, step time variability, SL variability, stance time variability, non-linear measures (gait smoothness, complexity, intensity) and stride frequency.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, step time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, stance, swing time, stance time, step time asymmetry, step time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>HS, for time, sance time variability,</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2017 Pau et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Vaist Terrier et al., 2011 Terrier et al., 2017 Foot Chung et al., 2017	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridge,UK), attached near COM. Tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Triaxial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L4-5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L4-5. Tri-axial accelerometer (G-Walk, BTS Bioengineering S,p.A., Italy) attached over L4-5. Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back, The other two IMUs positioned at each anke, just above the malleol. MVP-RF-8, MicroStone Co., Nagano, Japan) that contained a triax	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of rescription footwear on gait quality in patients. Differentiating while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Differentiating PD and healthy controls. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures. Differentiating PD and healthy controls. Pelineating patients with Alzheimer's disease (AD) from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability, at non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time symmetry and SL symmetry.</li> <li>Stride frequency, SL, gait symmetry and regularity.</li> <li>GV, SL, swing time, stance time, step time variability and double support time.</li> <li>GV and step time variability, step time, swing time, stance time, step time variability, SL variability, stance time variability, swing time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, step and stride regularity, gait symmetry, step time variability, stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, cadence, stance duration, swing time, stance time, step time symmetry, suity gait variability, stride time variability, GV variability, stride length variability, stride frequency.</li> <li>Step court, mean bout length, step time, swing time, stance time, step time symmetry, swing time saymmetry, stance time asymmetry, Starsy time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, stance, swing and double support phase duration.</li> <li>Step time, cadence, stance duration, swing duration and double support duration.</li> <li>HS, TO, stride length, stance time, swing time, stride time variability, step time variability, stance time variability, step time variability.</li> <li>Stride length, GV cadence, stance duration, swing duration and double support duration.</li> <li>HS, TO, stride time, step time, stance time, swing time, stride time variability, ste</li></ul>
Terrier & Reynard, 2015Awotidebe et al., 2016Barden et al., 2016Clermont et al., 2016Del Din et al., 2016Hatanaka et al., 2016Henderson et al., 2016Martinez-Ramirez et al., 2016Mutoh et al., 2016Pau et al., 2016Van Schooten et al., 2016Del Din et al., 2017Pau et al., 2017Pau et al., 2017Pau et al., 2017Pau et al., 2018Storm et al., 2018Vans Chooten et al., 2018Pau et al., 2017Pau et al., 2018Chung et al., 2017FootChung et al., 2017FootChung et al., 2017FootChung et al., 2017FootChung et al., 2017FootEar	Tri-axial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached over L3. tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Calt® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (MA-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, lust above the maleoli. MVP-RF-8, MicroStone Co., Nagano, Japan) that contained a triaxial angular rate gyroscope and a linear accelerometer were attached to a	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebeltar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Effect of texting while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Delineating PD and healthy controls. Delineating PD and healthy controls. Delineating patients with Alzheimer's disease (AD) from healthy controls from free-living gait. Relationship of patients with Alzheimer's disease (AD) from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step time, step time variability and non-linear measures (gait variability).</li> <li>Step count, stride time, stride time variability, SL variability, step time variability, stance time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry.</li> <li>GV, SL, swing time variability, GV variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time, swing time, stance time, step time, stance time, step time, variability, stance time variability, Stance time, swing time, stance time, step time variability, stance time variability, stance time variability, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and non-linear measures (gait control variability, stance time variability, stance time, swing time, stride time variability, step time variability, stance time variability, stance time variability, step count, GV</li> <li>Gatence, stride length, GV and non-linear measures (g</li></ul>
Terrier & Reynard, 2015Awotidebe et al., 2016Barden et al., 2016Clermont et al., 2016Del Din et al., 2016Hatanaka et al., 2016Henderson et al., 2016Hickey et al., 2016Martinez-Ramirez et al., 2016Pau et al., 2016Van Schooten et al., 2016Del Din et al., 2017Esser et al., 2018Pau et al., 2018Tanigawa et al., 2018VanstTerrier et al., 2017FootChung et al., 2017FootEarAtallah et al., 2012Atallah et al., 2014	Triaxial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Minamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer (Mi-M1110-HW, L5I Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Mc-M1110-HW, L5I Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Triaxial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at each ankle, just above the malleoli. MVP-RF-8, MicroStone Co., Nagano, Japan) that contained a triaxial angular rate gyroscope and a linear accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at at the level of the L3. Physilog system (BioAGM, Switzerland), triaxial accelerometer lateral waist. Tri-axial accelerometer w	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between knee osteoarthritis patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of rexting while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures. Differentiating PD and healthy controls. Pelineating patients with Alzheimer's disease (AD) from healthy controls from free-living gait. Pelineating patients with Alzheimer's disease (AD) from healthy controls.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, step time, step time variability, stance time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time, step time, step time, swing time, step time variability, and double support time.</li> <li>GV SL, swing time variability, step time variability and double support time.</li> <li>GV AL, swing time variability, step time, step time variability, stance time variability, stance time variability, stance time variability, swing time asymmetry, stance time, step time variability, stance time variability, swing time asymmetry, step time variability, SL variability, stance time variability, swing time asymmetry, step time variability, swing time asymmetry, step time variability, SMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, step time variability, stride length, gait symmetry, stance time variability, stride length, GV, stride time variability, GV variability, stride length, and stride frequency.</li> <li>Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, stance time variability, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Hsp time, cadence, stride length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Hsp time, variability, step time, stance time, swing time, stride time variability, step time variability, step time variabi</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Esser et al., 2017 Pau et al., 2017 Esser et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Vanst Tanigawa et al., 2018 Vanst Terrier et al., 2017 Foot Chung et al., 2017 Foot Chung et al., 2017 Foot Chung et al., 2017	Triaxial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Galt® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologias B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer and gyroscope) fixed to the lower back. Tri-axial accelerometer and gyroscope) fixed to the lower back. Tri-axial accelerometer were attached to a fixed belt at the level of the L3. Physilog system (BioAGM, Switzerland), triaxial accelerometer lateral waist. Tri-axial accelerometer were attached to a fixed belt at the level of the L3. Physilog system (BioAGM, Switzerland), triaxial accelerometer lateral waist. Tri-axial accelerometer on superior aspect of right foot. Foot pod (Garmin Ltd., Kansas City, USA) strapped to dorsum of foot. e-AR	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Effect of texting while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Differentiating PD and healthy controls. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures. Differentiating PD and healthy controls. Poel-operative recovery of orthopaedic patient. Poel-operative recovery of orthopaedic patient.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, Step time, step time variability, and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time, step time symmetry, swing time variability.</li> <li>GV, SL, addence, step time, step time variability and double support time.</li> <li>GV and step time variability.</li> <li>GV, SL, swing time variability, step time, swing time, stance time, step time variability, stance time variability, sture asymmetry, step time variability, stance time variability, swing time asymmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, gait symmetry, stap time symmetry, stance time variability, non-linear measures (gait smoothness, complexity, intensity) and stride frequency.</li> <li>Step count, mean bout length, step time, swing time stance time, step time variability, step time variability.</li> <li>Cadence, speed, stride length, Stance, sing and double support phase duration.</li> <li>Step time, astep time, step count, GV cadence duration, swing duration and double support duration.</li> <li>Step time, cadence, stride length, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and SL variability.</li> <li>Cadence, speed, stride length, GV and SL variability.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, cadence, stance time, swing time, stride time variabili</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Martinez-Ramirez et al., 2016 Mattinez-Ramirez et al., 2016 Van Schooten et al., 2016 Van Schooten et al., 2017 Pau et al., 2017 Pau et al., 2017 Pau et al., 2017 Esser et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Tanigawa et al., 2018 Vaist Tanigawa et al., 2018 Vaist Tanigawa et al., 2018 Chung et al., 2017 Foot Chung et al., 2017 Foot Chung et al., 2017 Foot Chung et al., 2014 Angthong & Veljkovic, 2018	Triaxial accelerometer (Physilog <sup>®</sup> System, Gaitup, Lausanne, Switzerland) 5cm below sternal notch. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5. Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3. tri-axial accelerometer (GENEActiv, Cambridge, UK), attached over L3. tri-axial accelerometer (Axivity AX3, York, UK) over L5. Locometrix (tri-axial accelerometer) over L3-4. triaxial accelerometer (Mimamori-Cait® System, LSI Medience Corp., Tokyo, Japan) back of waist. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk. Axivity AX3 sensor (Axivity, York, UK) located on L5. Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3. Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3. IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (Axivity AX3, York, UK) on the lower back. Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5. Tri-axial accelerometer (Avivity AX3, York, UK) on the lower back. MVP-RF-8, MicroStone Co., Nagano, Japan) that contained a triaxial angular rate gyroscope and a linear accelerometer were attached to a fixed belt at the level of the L3. Physilog system (BioAGM, Switzerland), triaxial accelerometer lateral waist. Tri-axial accelerometer were attached to a fixed belt at the level of the L3. Physilog system (BioAGM, Switzerland), triaxial accelerometer lateral waist. Tri-axial accelerometer on superior aspect of right foot. Foxt pad (Garmin Ltd., Kansas City, USA) strap	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between RD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Gait characteristics in fallers and non-fallers with and without PD. Characterise gait in MS patients in laboratory and free-living conditions and determine severity. Felationship of lumbopelvic pain with gait in pregnant patients. Assess the effect of prescription footwear on gait quality in patients after ankle/foot fractures. Delineating PD and healthy controls. Palineating patients with Alzheimer's disease (AD) from healthy controls. Palineating patients with Alzheimer's disease (AD) from healthy controls. Post-operative recovery of orthopaedic patient. To assess recovery in anterior cruciate ligament injury patients after surgery.	<ul> <li>GV, non-linear measures (gait stability), RMS and walk-ratio.</li> <li>GV, SL, stride length and cadence.</li> <li>Stride time, step time, stride regularity, step regularity and gait symmetry.</li> <li>Step count, stride time, stride time variability, Step time, step time variability, and non-linear measures (gait variability).</li> <li>GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, stance time, step time symmetry, swing time symmetry, summetry, summetry, summetry, summetry, stance time, step time, step time, stance time, step time variability, and double support time.</li> <li>GV, SL, swing time variability, step time, suing time, stance time, step time variability, stance time variability, step time variability, step time asymmetry, stance time asymmetry and step length asymmetry.</li> <li>GV, SL, swing time variability, gait symmetry, step time variability, RMS, gait stability and HR.</li> <li>Cadence, SL and GV.</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Stride length, GV, stride time variability, GV variability, stride length variability, stride length, stride symmetry, stride length variability, stride length, stride symmetry, stance time symmetry, stance time asymmetry, stance time asymmetry, stance time variability, stance time variability, stance time, stride time variability, step time, variability, stride length, GV, cadence, stance duration, swing duration and double support duration.</li> <li>Step count, mean bout length, Step time, swing ime, stance time, step time variability, step time, stance time, step duration.</li> <li>Step count, mean bout length, GV and non-linear measures (gait control variables).</li> <li>Stride length, GV, cadence, stance duration, swing duration and double support</li></ul>
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Yan Schooten et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Pau et al., 2017 Esser et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Tanigawa et al., 2018 Tanigawa et al., 2018 Tarrier et al., 2017 Foot Chung et al., 2017 Foot Chung et al., 2017 Foot Chung et al., 2014 Jarchi et al., 2014 Jarchi et al., 2014	<ul> <li>Tri-axial accelerometer (Physilog<sup>4</sup> System, Gaitup, Lausanne, Switzerland) Som below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Minamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HV, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer (Avivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Avivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back.</li> <li>Tri-axial accelerometer were attached to a fixed beti at the level of the L3.</li> <li>Physilog</li></ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait analysis to detect peripheral neuropathy in diabetes patients. Effect of texting while walking on gait in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and the e-living conditions and determine severity. Relationship of lumbopetvic pain with gait in pregnant patients. Differentiating PD and healthy controls. Delineating patients with Azhelmer's disease (AD) from healthy controls. Relationship of patients with Azhelmer's disease (AD) from healthy controls. Relationship of patients with Azhelmer's disease (AD) from healthy controls. Relationship of patient-reported outcomes and quality-of-life with gait characteristics in patients with foot-ankle controls. Post-operative recovery of orthopaedic patient.	GV, non-linear measures (gait stability), RMS and walk-ratio. GV, SL, stride length and cadence. Stride time, step time, stride regularity, step regularity and gait symmetry. Step count, stride time, stride time variability, step time, step time variability, stance time variability, step time, swing time, stance time, step time symmetry, swing time symmetry, stance time symmetry and SL symmetry. Stride frequency, SL, gait symmetry and regularity. GV, SL, swing time variability, step time, stance time, step time variability, stance time variability, stance time variability, swing time variability, step time, swing time, stance time, step time variability, stance time variability, swing time asymmetry, step time symmetry, stance time asymmetry and step length asymmetry. GV, SL, swing time variability, gait symmetry, step time variability, RMS, gait stability and HR. Cadence, SL and GV. Stride length, GV, cadence, stance duration, swing duration and double support duration. Stride length, GV, cadence, stance duration, swing duration and double support duration. Stride length, GV, cadence, stance duration, swing duration and double support duration. Stride length, GV, cadence, stance duration, swing duration and double support duration. Step count, mean bout length, step time, swing time, stance time, step time asymmetry, suit warability, stance time variability. GV avaiability, stride length qait symmetry, gait variability, stance time asymmetry, Sta asymmetry, step velocity, SL, swing time variability, step time variability, stance time variability. GV and SL variability. Step count, mean bout length, step time, swing duration and double support duration. HS pto time, stance stride length, GV and non-linear measures (gait control variable). Stride length, GV, cadence, stance duration, swing duration and double support duration. HS, D, stride time, step time, stance time, swing time, stride time variability, step time variability, stance time variability, swing time variability. Gadence, s
Terrier & Reynard, 2015 Awotidebe et al., 2016 Barden et al., 2016 Clermont et al., 2016 Del Din et al., 2016 Hatanaka et al., 2016 Henderson et al., 2016 Martinez-Ramirez et al., 2016 Mutoh et al., 2016 Pau et al., 2016 Van Schooten et al., 2016 Del Din et al., 2017 Pau et al., 2017 Esser et al., 2017 Esser et al., 2018 Storm et al., 2018 Storm et al., 2018 Tanigawa et al., 2018 Tanigawa et al., 2018 Tanigawa et al., 2018 Chung et al., 2017 Foot Chung et al., 2017 Foot Chung et al., 2017 Foot Chung et al., 2014 Jarchi et al., 2014 Jarchi et al., 2016 Smart device Kosse et al., 2016	<ul> <li>Tri-axial accelerometer (Physilog<sup>a</sup> System, Gaitup, Lausanne, Switzerland) Som below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridgeshire, UK) attached over L3.</li> <li>tri-axial accelerometer (GENEActiv, Cambridge, UK), attached near COM.</li> <li>Tri-axial accelerometer (Axivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Avivity AX3 sensor (Axivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer fixed over L3.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) over L3.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L5.</li> <li>Tri-axial accelerometer fixed to participant's sacrum.</li> <li>IMU (in-axial accelerometer ad gyroscope) fixed to the lower back.</li> <li>Tri-axial accelerometer fixed to participant's sacrum.</li> <li>IMU (in-axial accelerometer ad gyroscope) fixed to the lower back.</li> <li>Tri-axial accelerometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>Tri-axial accelerometer fixed to a fixed beit at the lewel of the L3.</li> <li>Physilog system (BioAGM, Switzerland), triaxial accelerometer lateral waist.</li> <li>Tri-axial accelerometer were attached to a fixed beit at the lewel of the L3.</li> <li>Physilog system (BioAGM, Switzerland), triaxial accelerometer later</li></ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Delemating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebeliar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait characteristics as a predictor of falls in older subjects. Gait characteristics in fallers and non-fallers with and without PD. Gait in early MS subjects compared to healthy control. Characterise gait in MS patients in laboratory and free-living controls. Effect of texting while walking ong alt in MS patients compared to healthy controls. Characterise gait in MS patients in laboratory and free-living controls and determine severity. Relationship of lumbopelvic pain with gait in pregnant patients. Differentiating PD and healthy controls. Delineating patients with Alzheimer's disease (AD) from healthy controls from free-living gait. Delineating patients with Alzheimer's disease (AD) from healthy controls. Relationship of patient-reported outcomes and quality-of-life with gait characteristics in patients with foot-ankie conditions. Post-operative recovery of orthopaedic patient. To assess gait variability changes related to aging.	GV, non-inear measures (gait stability), RMS and walk-ratio. GV, SL, stride length and cadence. Stride time, step time, stride time variability, step regularity and gait symmetry. Step count, stride time, stride time variability, SL variability, step time variability and non-linear measures (gait variability). GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, stwing time, stance time, step time variability and double support time. GV SL, swing time variability. GV, SL, cadence, step time, step time variability and double support time. GV and step time variability, step time, step time variability, stance time asymmetry and step length asymmetry. GV, step and stride regularity, gait symmetry, step time variability, RMS, gait stability and HR. Cadence, SL and GV. Stride length, GV, cadence, stance duration, swing duration and double support duration. Stride length, GV, cadence, stance duration, swing duration and double support duration. Stride length, GV, cadence, stance duration, swing duration and double support duration. Stride length, GV, stride time variability, GV variability, stride length variability, stride frequency, Step count, mean bout length, step time, swing time, stance time, step time asymmetry, swing time asymmetry, stance time variability, GV and Ion-linear measures (gait control variable). Stride length, GV, cadence, stance duration, swing duration and double support duration. Step count, mean bout length, step time, stance time, step time asymmetry, swing time variability, step time variability, step time, stance time, swing time, stride time variability, step time variability, step time variability, step time, stance time, swing time, stride time variability, step time variability, stence time variability, step symmetry. Cadence, stride length, step symmetry, and stride regularity. Cadence, step regularity and non-linear measures (gait control variable). Stride regularity and stride symmetry.
Terrier & Reynard, 2015Awotidebe et al., 2016Barden et al., 2016Clermont et al., 2016Del Din et al., 2016Hatanaka et al., 2016Henderson et al., 2016Martinez-Ramirez et al., 2016Mutoh et al., 2016Pau et al., 2017Pau et al., 2017Esser et al., 2018Pau et al., 2018Storm et al., 2018Tanigawa et al., 2018Vanschooten et al., 2018Chung et al., 2017Faser et al., 2018Fanigawa et al., 2018Fanigawa et al., 2018Storm et al., 2017FootChung et al., 2016Smart deviceKosse et al., 2016Mobbs et al., 2018	<ul> <li>Tri-axial accelerometer (Physilog<sup>a</sup> System, Gaitup, Lausanne, Switzerland) Som below sternal notch.</li> <li>IMU containing tri-axial accelerometer, gyroscope and magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L5.</li> <li>Triaxial accelerometer (GENEActiv, Cambridge.UK), attached near COM.</li> <li>Tri-axial accelerometer (Avivity AX3, York, UK) over L5.</li> <li>Locometrix (tri-axial accelerometer) over L3-4.</li> <li>triaxial accelerometer (Mimamori-Gait® System, LSI Medience Corp., Tokyo, Japan) back of waist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer placed on lower trunk.</li> <li>Axivity AX3 sensor (Avivity, York, UK) located on L5.</li> <li>Tracker MTx (XSENS; Xsens Technologies B.V. Enschede, The Netherlands) featuring tri-axis accelerometer, tri-axis gyroscope, tri-axis magnetometer (G-Walk, BTS Bioengineering S.p.A., Italy) attached over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer (Avivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (MG-M1110-HW, LSI Medience, Tokyo, Japan) back of vaist.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer over L4-5.</li> <li>DynaPort MiniMod (McRoberts BV, The Hague, The Netherlands) consisting of a triaxial accelerometer (Avivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Avivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (Avivity AX3, York, UK) on the lower back.</li> <li>Tri-axial accelerometer (MoveMonitor, Version 2.8.1, Mc Roberts, The Hague, The Netherlands) positioned at the lower back. The other two IMUs positioned at tach anale, usita boxet lower back.</li> <li>Tri-axial accelerometer wave attached to a fixed belt at the level of the L3.</li> <li>Physlog system (BioAGM, Switzerland), triaxial accelerometer lateral waist.</li> <li>Tri-axial accelerometer wave attach</li></ul>	Effect of aging on gait parameters. Delineating between type 2 diabetes patients and healthy controls. Compare regularity and symmetry of gait between knee osteoarthritis (OA) and healthy controls. Delineating between PD patients and age-matched controls. Delineating between PD patients and age-matched controls. Determining risk of developing AD from MCI based on gait. Gait comparison in Progressive Supranuclear Palsy and PD and delineating from healthy controls. Effect of rivastigmine on gait variability in PD. Differentiating patients with spinocerebellar ataxia type-6 from healthy controls. Effects of hippotherapy on gait and balance ability of children and adolescents with cerebral palsy. Gait measures in MS and correlation with patient-reported outcomes. Determining MS severity. Gait characteristics as a predictor of falls in older subjects. Gait in early MS subjects compared to healthy control. Characterise gait in MS patients in laboratory and free-living controls. Characterise gait in MS patients in laboratory and free-living controls and determine severity. Relationship of fumbopheric paln with gait in pregnant patients. Delineating PD and healthy controls. Poelineating PD and healthy controls. Poelineating patients with Alzheimer's disease (AD) from healthy controls from free-living gait. Poel-operative recovery of orthopaedic patient. To assess recovery in anterior cruciate ligament injury patients after surgery. Assess gait variability changes related to aging. Gait analysis for objective recovery measures following lumbar microdiscectomy.	GV, non-linear measures (gait stability), RMS and walk-ratio. GV, SL, stride length and cadence. Stride time, step time, stride time variability, step regularity and gait symmetry. Step count, stride time, stride time variability, SL variability, step time variability and non-linear measures (gait varability). GV, SL, swing time variability, GV variability, SL variability, step time variability, stance time variability, step time, swing time, stance time, step time variability and double support time. GV, SL, swing time variability, Step time, step time variability, SL variability, stance time variability, swing time variability, step time, step time variability, SL variability, stance time variability, swing time variability, step time, step time variability, SL variability, stance time variability, swing time asymmetry, step time variability, RMS, gait stability and HR. Cadence, SL and GV. Stride length, GV, cadence, stance duration, swing duration and double support duration. Stride length, GV, cadence, stance duration, swing duration and double support duration. Stride length, GV, stride time variability, GV variability, stride length variability, stride frequency. Step count, mean bout length, step time, stem etime, step time saymmetry, suite is asymmetry, stance time variability, GV and Stride length variability, stride length, GV, stride length, GV and non-linear measures (gait control variability. Cadence, speed, stride length, GV and non-linear measures (gait control variability. Stride length, GV, cadence, stance duration, swing duration and double support duration. HS, fork stride time, step time, step time, swing time, stride time variability, step time variability, stence time variability, soluting wariability. Step count, GV Cadence, stride length, GV cadence, stance time, swing time stride time variability, step time variability, stence time variability, soluting variability. Step count, GV Cadence, step regularity and non-linear measures (intensity, dynamic stability). Stride length, stride freq

	Table S3	Risk of bias	assessment	of validity	and re	liability	studies
--	----------	--------------	------------	-------------	--------	-----------	---------

		Patient S	election		In	idex Tes	st	Refer	ence Sta	andard	Flow	and Tin	ning	Overall
Article (author, year) -	1.1	1.2	1.3	1.4	2.1	2.2	2.3	3.1	3.2	3.3	4.1	4.2	4.3	5.1
Atallah et al., 2014	CS	Y	Y	Y	Y	NA	Y	Y	Y	Y	Y	Y	Y	++
Bautmans et al., 2011	CS	Y	Y	Y	NA	NA	Y	NA	NA	NA	NA	NA	Y	++
Brandes et al., 2006	CS	Y	Y	Y	Y	NA	Y	CS	Y	CS	Y	Y	Y	+
Bugane <i>et al.</i> , 2012	CS	Y	Y	Y	Y	NA	Υ	Y	Y	Y	Y	Y	Y	++
Byun <i>et al.</i> , 2016	CS	Y	Y	Y	Y	NA	Υ	Y	Y	Y	Y	Y	CS	++
Dalton <i>et al.</i> , 2013	CS	Y	Y	Y	Y	NA	Υ	Y	Υ	Y	Y	Y	Y	++
De Bruin <i>et al.</i> , 2012	Ν	Y	Y	CS	NA	NA	Υ	NA	NA	NA	NA	NA	Ν	+
De Ridder et al., 2019	CS	Y	Y	Y	Y	NA	Υ	Y	Υ	Y	Y	Y	CS	++
Esser <i>et al.</i> , 2012	CS	Y	Y	Y	Y	NA	Υ	Y	Υ	Y	Y	Y	CS	++
Godfrey et al, 2014	CS	Y	Y	Y	Υ	NA	Υ	Υ	Y	Y	Y	Y	CS	++
Godfrey et al, 2015	CS	Y	Y	CS	Υ	NA	Υ	Υ	Y	Y	Y	Y	Ν	+
Grimpampi <i>et al.</i> , 2015	CS	Y	Y	Y	NA	NA	Υ	NA	NA	NA	NA	NA	Y	++
Hartmann <i>et al.</i> , 2009	CS	Y	Y	Y	Y	NA	Υ	Y	Y	Y	Y	Y	Y	++
Hartmann <i>et al.</i> , 2009 (different surfaces)	CS	Y	Y	Y	NA	NA	Y	NA	NA	NA	NA	NA	Ν	+
Henriksen <i>et al.</i> , 2004	CS	Y	Y	Y	NA	NA	Y	NA	NA	NA	NA	NA	Y	++
Hickey <i>et al.</i> , 2016	CS	Y	Y	CS	Y	NA	Y	Y	Y	Y	Y	Y	Y	++
Houdijk <i>et al.</i> , 2008	CS	Y	Y	Y	Y	NA	Y	Y	Y	Y	Y	Y	Y	++
Jarchi e <i>t al.</i> , 2014	CS	Y	Y	CS	Y	NA	Y	Y	Y	Y	Y	Y	Y	++
Jarchi <i>et al.</i> , 2015	CS	Y	Y	Y	Y	NA	Y	Y	Y	Y	Y	Y	Ν	+
Jarchi <i>et al.</i> , 2016	CS	Y	Y	CS	Y	NA	Y	Y	Y	Y	Y	Y	Y	++
Köse <i>et al.</i> , 2012	CS	Y	Y	CS	Y	NA	Y	Y	Y	Y	Y	Y	Y	++
LeMoyne et al., 2010	Ν	Y	Y	CS	NA	NA	Y	NA	NA	NA	NA	NA	Y	+
Li <i>et al.</i> , 2010	CS	Y	Y	Y	Υ	NA	Y	Y	Y	Y	Y	Y	Y	++
Lim & Lee, 2017	CS	Y	Y	Y	Y	NA	Y	Y	Y	Y	Y	Y	CS	++
Maqbool <i>et al.</i> , 2017	CS	Y	Y	CS	Υ	NA	Y	Y	Y	Y	Y	Y	Y	++
McCamley et al., 2012	CS	Y	Y	Y	Υ	NA	Y	Y	Y	Y	Y	Y	CS	++
Oyake <i>et al.</i> , 2017	CS	Y	Y	Y	Y	NA	Y	Y	Y	Y	Y	Y	CS	++
Park & Woo, 2015	CS	Y	Y	CS	Υ	NA	Y	Y	Y	Y	Y	Y	CS	+
Pepa <i>et al.</i> , 2017	CS	Y	Y	CS	Y	NA	Y	Y	Y	Y	Y	Y	CS	+
Sabatini <i>et al.</i> , 2005	CS	Y	Y	CS	Υ	NA	Y	Y	Y	Y	Y	Y	Y	++
Sejdic et al., 2016	CS	Y	Y	Y	Y	NA	Y	Y	Y	Y	Y	Y	CS	++
Silsupadol et al., 2017	CS	Y	Y	CS	Y	NA	Υ	Y	Y	Y	Y	Y	Y	++
Song & Kim, 2018	CS	Y	Y	Y	Y	NA	Υ	Y	Y	Y	Y	Y	CS	++
Storm et al., 2016	CS	Y	Y	Y	Υ	NA	Υ	Y	Y	Y	Y	Y	Y	++
Storm <i>et al.</i> , 2018	CS	Y	Y	Y	Υ	NA	Υ	Y	Y	Y	Y	Y	Ν	+
Trojaniello <i>et al.</i> , 2014	CS	Y	Y	Y	Υ	NA	Υ	Y	Y	Y	Y	Y	Y	++
Trojaniello <i>et al.</i> , 2015	CS	Υ	Y	Y	Y	NA	Y	Y	Y	Y	Y	Y	CS	++
Zago <i>et al.</i> , 2018	CS	Y	Y	Y	Y	NA	Υ	Y	Y	Υ	Y	Y	CS	++
Zijlstra & Hof, 2003	CS	Y	Y	Y	Y	NA	Y	Y	Y	Y	Y	Y	Y	++
Zijlstra & Zijlstra, 2013	CS	Y	Y	Y	Y	NA	Y	Y	CS	Y	Y	Y	Y	++
Collett <i>et al.</i> , 2014*						As	ssessec	l using N	IOS					
Esser <i>et al.</i> , 2011*						As	ssessec	l using N	IOS					

Y, yes; N, no; NA, not applicable; CS, can't say; "+" denotes acceptable quality in minimizing bias; "++" denotes high quality in minimizing bias; NOS, Newcastle-Ottawa Scale. \*, refer Appendix 1.

Study (Author, Year)	Selection	Comparability	Exposure	Results
Angthong, 2018	2	2	2	Fair
Atallah, 2014	2	1	2	Fair
Auvinet, 2003	3	0	2	Poor
Awotidebe, 2016	4	1	2	Good
Barden, 2016	3	2	2	Good
Bautmans, 2011	4	2	2	Good
Bolink, 2012	3	1	2	Good
Chung, 2012	1	1	2	Poor
Clermont, 2016	3	1	2	Good
Collett, 2014	3	2	2	Good
Dalton, 2013	3	2	2	Good
De Bruin, 2012	2	2	2	Fair
Del Din, 2016	3	1	2	Good
Del Din, 2017	3	1	2	Good
Demonceau, 2015	3	2	2	Good
Esser, 2011	1	0	1	Poor
Esser, 2013	4	2	2	Good
Esser, 2018	3	1	2	Good
Gillain, 2016	2	2	2	Fair
Hatanaka, 2016	3	1	2	Good
Herman, 2014	3	2	2	Good
Hickey, 2016	4	1	2	Good
Hojan, 2014	3	1	2	Good
losa, 2013	2	2	2	Fair
Jarchi, 2016	2	1	1	Poor
Kosse, 2016	3	1	2	Good
Lamoth 2011	3	1	2	Good
Lamoth, 2010	3	1	1	Poor
Manikowska, 2013 (postmenopausal women)	3	1	2	Good
Maquet, 2010	3	2	2	Good
Martinez-Ramirez, 2015	3	1	1	Poor
Martinez-Ramirez, 2016	3	1	2	Good
Matsushima, 2015	2	1	2	Fair
Meijer, 2011	3	2	2	Good
Mizuike, 2009	4	1	2	Good
Moe-Nilssen, 2003	4	2	3	Good
Pau, 2016	4	0	2	Poor
Pau, 2017	4	0	2	Poor
Pau, 2018	3	1	2	Good
Perrochon, 2015	2	2	2	Fair

Appendix 1 Risk of bias assessment of clinical applicability studies

Rapp, 2015	3	2	1	Poor
Saether, 2014	4	2	2	Good
Soangra, 2018	2	1	2	Fair
Storm, 2018	3	1	2	Good
Tanigawa, 2018	3	0	2	Poor
Terrier, 2009	1	2	2	Poor
Terrier, 2015	3	1	2	Good
Terrier, 2017	3	1	2	Good
Van Schooten, 2016	3	2	2	Good
Yang, 2011	3	0	2	Poor

			Ra	ndom	ised	contro	ol tria	ls (RCT	-)			
Study (Author,						Inter	nal va	lidity				Overall
Year)	1.1	1.2	1.3	1.4	1.5	1.6	1.7	1	.8	1.9	1.10	assessment
								I(%)	C(%)			
Doi, 2013*	Y	CS	CS	CS	Y	Υ	Υ	4	8	Y	NA	+
Henderson, 2016*	Υ	Υ	Y	Y	CS	CS	Y	15	11	Y	NA	++
Pau, 2014*	Y	Y	CS	CS	CS	Y	Y	0	0	Y	NA	+

Not as	ssessed
Houdijk, 2008	Assessed using SIGN
Arvin, 2015	Self-controlled before-after study
Manikowska, 2013	Case series
Mobbs, 2018	Case report
Mutoh, 2016	Case series

NOS interpretation:

**Good quality**:  $\geq$ 3 stars in selection domain AND  $\geq$  1 star in comparability domain AND  $\geq$ 2 stars in outcome/exposure domain.

**Fair quality**: 2 stars in selection domain AND  $\geq$  1 star in comparability domain AND  $\geq$  2 stars in outcome/exposure domain.

**Poor quality**:  $\leq$  1 star in selection domain OR 0 stars in comparability domain OR  $\leq$  1 star in outcome/exposure domain.

Y, yes; N, no; NA, not applicable; CS, can't say; "+" denotes acceptable quality in minimizing bias; "++" denotes high quality in minimizing bias; I (%), percentage dropout in intervention group; C (%), percentage dropout in control group. \*, RCTs were assessed using SIGN checklist for RCTs.